{
  "drug": "Olaparib",
  "fetched_at": "2026-02-09T13:06:48.187530+00:00",
  "drug_class_search": {
    "fetched_at": "2026-02-09T13:06:48.187530+00:00",
    "results": [
      {
        "title": "Olaparib | C24H23FN4O3 | CID 23725625 - PubChem - NIH",
        "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib",
        "content": "FDA Pharmacology Summary\n\nOlaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.\n\nFDA Pharm Classes\n\n2 of 2 items\n\nNon-Proprietary Name\n\nOLAPARIB \n\nPharmacological Classes\n\nPoly(ADP-Ribose) Polymerase Inhibitor [EPC]; Poly(ADP-Ribose) Polymerase Inhibitors [MoA] \n\nNational Drug Code (NDC) Directory\n\n### 7.4 ATC Code\n\nL01XK01 \n\nEuropean Medicines Agency (EMA)\n\nL - Antineoplastic and immunomodulating agents\n\nL01 - Antineoplastic agents\n\nL01X - Other antineoplastic agents\n\nL01XK - Poly (adp-ribose) polymerase (parp) inhibitors\n\nL01XK01 - Olaparib\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\nATCvet Code\n\nQL - Antineoplastic and immunomodulating agents\n\nQL01 - Antineoplastic agents [...] DrugBank\n\n### 7.2 MeSH Pharmacological Classification\n\nAntineoplastic Agents\n\nSubstances that inhibit or prevent the proliferation of NEOPLASMS. \n\nMedical Subject Headings (MeSH)\n\nPoly(ADP-ribose) Polymerase Inhibitors\n\nChemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. \n\nMedical Subject Headings (MeSH)\n\n### 7.3 FDA Pharmacological Classification\n\n1 of 2 items\n\nFDA UNII\n\nWOH1JD9AR8 \n\nActive Moiety\n\nOLAPARIB \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Poly(ADP-Ribose) Polymerase Inhibitor \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Poly(ADP-Ribose) Polymerase Inhibitors \n\nFDA Pharmacology Summary [...] ChEBI\n\nOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.\n\nDrugBank\n\nOlaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.\n\nFDA Pharm Classes\n\nView More...\n\n1 Structures\n\n### 1.1 2D Structure\n\nStructure Search\n\nGet Image",
        "raw_content": "Olaparib | C24H23FN4O3 | CID 23725625 - PubChem\n===============\n\nAn official website of the United States government\n\nHere is how you know\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\n\n**The site is secure.**\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n[NIH National Library of Medicine NCBI](https://www.ncbi.nlm.nih.gov/)\n\n[PubChem](https://pubchem.ncbi.nlm.nih.gov/)\n*   [About](https://pubchem.ncbi.nlm.nih.gov/docs/about)\n*   [Docs](https://pubchem.ncbi.nlm.nih.gov/docs)\n*   [Submit](https://pubchem.ncbi.nlm.nih.gov/submit/)\n*   [Contact](https://pubchem.ncbi.nlm.nih.gov/docs/contact)\n*   Theme Settings \n\nSearch PubChem \n\nDraw\n\nID File\n\nSubmit search\n\nAdvanced Search\n\n[Search History](https://pubchem.ncbi.nlm.nih.gov/history)\n\n[Help](https://pubchem.ncbi.nlm.nih.gov/docs/quick-search)\n\n[compound](https://pubchem.ncbi.nlm.nih.gov/compound/)\nOlaparib\n========\n\nPubChem CID\n\n23725625\n\nStructure\n\n[![Image 2: Olaparib_small.png](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=23725625&t=s)](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=2D-Structure \"Go to 2D Structure section\")\n\n[![Image 3: Olaparib_3D_Structure.png](https://pubchem.ncbi.nlm.nih.gov/image/img3d.cgi?&cid=23725625&t=s)](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=3D-Conformer \"Go to 3D Conformer section\")\n\nPrimary Hazards\n\n[![Image 4: Acute Toxic](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS06.svg) ![Image 5: Health Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg) ![Image 6: Environmental Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS09.svg)](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=GHS-Classification)\n\n[Laboratory Chemical Safety Summary (LCSS) Datasheet](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#datasheet=LCSS)\n\nMolecular Formula\n\n*   [C 24 H 23 FN 4 O 3](https://pubchem.ncbi.nlm.nih.gov/#query=C24H23FN4O3 \"Find all compounds that have this formula\")\n\nSynonyms\n\n*   Olaparib \n*   763113-22-0 \n*   AZD2281 \n*   Lynparza \n*   AZD-2281 \n\nView More...\n\nMolecular Weight\n\n434.5 g/mol\n\nComputed by PubChem 2.2 (PubChem release 2025.09.15)\n\nDates\n\n*   Create: 2008-02-11 \n*   Modify: 2026-01-24 \n\nDescription\n\nOlaparib is a member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of [2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid](https://pubchem.ncbi.nlm.nih.gov/compound/2-fluoro-5-%5B%284-oxo-3%2C4-dihydrophthalazin-1-yl%29methyl%5Dbenzoic%20acid) with the free amino group of N-(cyclpropylcarbonyl)[piperazine](https://pubchem.ncbi.nlm.nih.gov/compound/piperazine); used to treat advanced ovarian cancer. It has a role as an antineoplastic agent, an EC 2.4.2.30 ([NAD](https://pubchem.ncbi.nlm.nih.gov/compound/NAD)(+) [ADP](https://pubchem.ncbi.nlm.nih.gov/compound/ADP)-ribosyltransferase) inhibitor and an apoptosis inducer. It is a N-acylpiperazine, a member of cyclopropanes, a member of monofluorobenzenes and a member of phthalazines.\n\nChEBI\n\nOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.\n\nDrugBank\n\nOlaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.\n\nFDA Pharm Classes\n\nView More...\n\n1 Structures[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Structures&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 1.1 2D Structure[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=2D-Structure&fullscreen=true \"Open this section in a new browser window\")\n\nStructure Search\n\nGet Image\n\nDownload Coordinates\n\nChemical Structure Depiction\n\n![Image 7: Olaparib.png](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=23725625&t=l)\n\nFull screen Zoom in Zoom out\n\nPubChem\n\n### 1.2 3D Conformer[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=3D-Conformer&fullscreen=true \"Open this section in a new browser window\")\n\nStructure Search\n\nGet Image\n\nDownload Coordinates\n\nInteractive Chemical Structure Model\n\nBall and Stick\n\nSticks\n\nWire-Frame\n\nSpace-Filling\n\nShow Hydrogens\n\nAnimate\n\nFull screen Zoom in Zoom out\n\nFirst Previous\n\nConformer of 10\n\nNext Last\n\nPubChem\n\n2 Names and Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Names-and-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 2.1 Computed Descriptors[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Computed-Descriptors&fullscreen=true \"Open this section in a new browser window\")\n\n#### 2.1.1 IUPAC Name[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=IUPAC-Name&fullscreen=true \"Open this section in a new browser window\")\n\n4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2 _H_-phthalazin-1-one\n\nComputed by Lexichem TK 2.9.3 (PubChem release 2025.09.15)\n\nPubChem\n\n#### 2.1.2 InChI[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=InChI&fullscreen=true \"Open this section in a new browser window\")\n\nInChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30) \n\nComputed by InChI 1.07.4 (PubChem release 2025.09.15)\n\nPubChem\n\n#### 2.1.3 InChIKey[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=InChIKey&fullscreen=true \"Open this section in a new browser window\")\n\nFDLYAMZZIXQODN-UHFFFAOYSA-N \n\nComputed by InChI 1.07.4 (PubChem release 2025.09.15)\n\nPubChem\n\n#### 2.1.4 SMILES[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=SMILES&fullscreen=true \"Open this section in a new browser window\")\n\nC1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F \n\nComputed by OEChem 4.2.0 (PubChem release 2025.09.15)\n\nPubChem\n\n### 2.2 Molecular Formula[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Molecular-Formula&fullscreen=true \"Open this section in a new browser window\")\n\nC 24 H 23 FN 4 O 3\n\nComputed by PubChem 2.2 (PubChem release 2025.09.15)\n\nPubChem\n\n### 2.3 Other Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Other-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n\n#### 2.3.1 CAS[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=CAS&fullscreen=true \"Open this section in a new browser window\")\n\n[763113-22-0](https://commonchemistry.cas.org/detail?cas_rn=763113-22-0)\n\nCAS Common Chemistry; ChemIDplus; DrugBank; EPA DSSTox; European Chemicals Agency (ECHA); FDA Global Substance Registration System (GSRS)\n\n763113220 \n\nDTP/NCI\n\n#### 2.3.2 Deprecated CAS[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Deprecated-CAS&fullscreen=true \"Open this section in a new browser window\")\n\n1021843-02-6, 894104-70-2, 937799-91-2\n\nChemIDplus\n\n#### 2.3.3 European Community (EC) Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=European-Community-EC-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[642-941-5](https://chem.echa.europa.eu/100.170.811)\n\nEuropean Chemicals Agency (ECHA)\n\n#### 2.3.4 UNII[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=UNII&fullscreen=true \"Open this section in a new browser window\")\n\n[WOH1JD9AR8](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WOH1JD9AR8)\n\nFDA Global Substance Registration System (GSRS)\n\n#### 2.3.5 ChEBI ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ChEBI-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[CHEBI:83766](https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:83766)\n\nChEBI\n\n#### 2.3.6 ChEMBL ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ChEMBL-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[CHEMBL521686](https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL521686)\n\nChEMBL\n\n#### 2.3.7 DrugBank ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=DrugBank-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[DB09074](https://www.drugbank.ca/drugs/DB09074)\n\nDrugBank\n\n#### 2.3.8 DSSTox Substance ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=DSSTox-Substance-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[DTXSID60917988](https://comptox.epa.gov/dashboard/DTXSID60917988)\n\nEPA DSSTox\n\n#### 2.3.9 HMDB ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=HMDB-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[HMDB0255929](https://hmdb.ca/metabolites/HMDB0255929)\n\nHuman Metabolome Database (HMDB)\n\n#### 2.3.10 KEGG ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[D09730](https://www.kegg.jp/entry/D09730)\n\nKEGG\n\n#### 2.3.11 Metabolomics Workbench ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Metabolomics-Workbench-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[152129](https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=152129)\n\nMetabolomics Workbench\n\n#### 2.3.12 NCI Thesaurus Code[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NCI-Thesaurus-Code&fullscreen=true \"Open this section in a new browser window\")\n\n[C71721](https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71721)\n\nNCI Thesaurus (NCIt)\n\n#### 2.3.13 Nikkaji Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Nikkaji-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[J2.765.098H](http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J2.765.098H)\n\nJapan Chemical Substance Dictionary (Nikkaji)\n\n#### 2.3.14 NSC Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NSC-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[747856](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=747856)\n\nDTP/NCI\n\n[753686](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=753686)\n\nDTP/NCI\n\n#### 2.3.15 PharmGKB ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=PharmGKB-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[PA164920420](https://www.pharmgkb.org/chemical/PA164920420)\n\nPharmGKB\n\n#### 2.3.16 Pharos Ligand ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Pharos-Ligand-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[XMQM7BMR67PF](https://pharos.nih.gov/ligands/XMQM7BMR67PF)\n\nPharos\n\n#### 2.3.17 RXCUI[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=RXCUI&fullscreen=true \"Open this section in a new browser window\")\n\n[1597582](https://rxnav.nlm.nih.gov/id/rxnorm/1597582)\n\nNLM RxNorm Terminology\n\n#### 2.3.18 Wikidata[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Wikidata&fullscreen=true \"Open this section in a new browser window\")\n\n[Q7083106](https://www.wikidata.org/wiki/Q7083106)\n\nWikidata\n\n#### 2.3.19 Wikipedia[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Wikipedia&fullscreen=true \"Open this section in a new browser window\")\n\n[Olaparib](https://en.wikipedia.org/wiki/Olaparib)\n\nWikipedia\n\n### 2.4 Synonyms[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Synonyms&fullscreen=true \"Open this section in a new browser window\")\n\n#### 2.4.1 MeSH Entry Terms[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=MeSH-Entry-Terms&fullscreen=true \"Open this section in a new browser window\")\n\nMeSH Entry Terms for olaparib\n\nolaparib \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Lynparza\n\nLynparza \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for AZD 2281\n\n*   AZD 2281 \n*   AZD-2281 \n*   AZD2281 \n\nMedical Subject Headings (MeSH)\n\n#### 2.4.2 Depositor-Supplied Synonyms[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Depositor-Supplied-Synonyms&fullscreen=true \"Open this section in a new browser window\")\n\n*   [Olaparib](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [763113-22-0](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22763113-22-0%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD2281](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD2281%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Lynparza](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Lynparza%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD-2281](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD-2281%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [KU-0059436](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22KU-0059436%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD 2281](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD%202281%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [KU-59436](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22KU-59436%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [WOH1JD9AR8](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22WOH1JD9AR8%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparibum](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparibum%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZ2281](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZ2281%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NSC-747856](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC-747856%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B%5B3-%5B4-(Cyclopropanecarbonyl)piperazine-1-carbonyl%5D-4-fluorophenyl%5Dmethyl%5D-2H-phthalazin-1-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZ-2281](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZ-2281%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [CHEBI:83766](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CHEBI%3A83766%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [DTXSID60917988](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22DTXSID60917988%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-(3-%7B%5B4-(Cyclopropylcarbonyl)piperazin-1-Yl%5Dcarbonyl%7D-4-Fluorobenzyl)phthalazin-1(2h)-One%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [KEYLYNK-010 COMPONENT OLAPARIB](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22KEYLYNK-010%20COMPONENT%20OLAPARIB%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%7B%5B3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl%5Dmethyl%7D-1%2C2-dihydrophthalazin-1-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B(3-%7B%5B4-(Cyclopropylcarbonyl)piperazin-1-yl%5Dcarbonyl%7D-4-fluorophenyl)methyl%5Dphthalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-(3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-(3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-((3-((4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)PHTHALAZIN-1(2H)-ONE](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-((3-((4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)PHTHALAZIN-1(2H)-ONE%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-((3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorophenyl)methyl)-2H-phthalazin-1-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-((3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorophenyl)methyl)-2H-phthalazin-1-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-((3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl)methyl)-1,2-dihydrophthalazin-1-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-((3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl)methyl)-1%2C2-dihydrophthalazin-1-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-((3-%7B(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl%7D-4-fluorophenyl)methyl)phthalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [RefChem:57006](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22RefChem%3A57006%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [PARP inhibitor AZD2281](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PARP%20inhibitor%20AZD2281%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [L01XX46](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22L01XX46%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [DTXCID001346944](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22DTXCID001346944%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221-(Cyclopropylcarbonyl)-4-%5B5-%5B(3%2C4-dihydro-4-oxo-1-phthalazinyl)methyl%5D-2-fluorobenzoyl%5Dpiperazine%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (AZD2281, Ku-0059436)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(AZD2281%2C%20Ku-0059436)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB cpd](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20cpd%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (AZD-2281)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(AZD-2281)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [MFCD13185161](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MFCD13185161%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib [USAN:INN]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20%5BUSAN%3AINN%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [C24H23FN4O3](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22C24H23FN4O3%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [UNII-WOH1JD9AR8](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22UNII-WOH1JD9AR8%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl%5D-2H-phthalazin-1-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [KU59436](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22KU59436%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (DISCONTINUED)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(DISCONTINUED)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B(3-%7B%5B4-Cyclopropylcarbonyl)piperazin-4-yl%5Dcarbonyl%7D-4-fluorophenyl)methyl%5Dphtalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B3-%5B4-(Cyclopropanecarbonyl)piperazine-1-carbonyl%5D-4-fluorobenzyl%5Dphthalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib [INN]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20%5BINN%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (AZD2281; Ku-0059436)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(AZD2281%3B%20Ku-0059436)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (AZD2281)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(AZD2281)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib, KU-0059436](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%2C%20KU-0059436%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD221](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD221%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [937799-91-2](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22937799-91-2%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Lynparza (TN)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Lynparza%20(TN)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [09L](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%2209L%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone; AZD 2281; KU 0059436; KU 59436; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine;](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B%5B3-%5B%5B4-(Cyclopropylcarbonyl)-1-piperazinyl%5Dcarbonyl%5D-4-fluorophenyl%5Dmethyl%5D-1(2H)-phthalazinone%3B%20AZD%202281%3B%20KU%200059436%3B%20KU%2059436%3B%201-(Cyclopropylcarbonyl)-4-%5B5-%5B(3%2C4-dihydro-4-oxo-1-phthalazinyl)methyl%5D-2-fluorobenzoyl%5Dpiperazine%3B%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (Standard)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(Standard)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD2281(olaparib)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD2281(olaparib)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [KU 59436](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22KU%2059436%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [USAN]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BUSAN%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [JAN]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BJAN%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [MI]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BMI%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [VANDF]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BVANDF%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [MART.]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BMART.%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [WHO-DD]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BWHO-DD%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib (JAN/USAN/INN)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20(JAN%2FUSAN%2FINN)%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B%5B3-%5B%5B4-(Cyclopropylcarbonyl)-1-piperazinyl%5Dcarbonyl%5D-4-fluorophenyl%5Dmethyl%5D-1(2H)-phthalazinone%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD-2281 (Olaparib)?](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD-2281%20(Olaparib)%3F%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [MLS006010185](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS006010185%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Olaparib - Bio-X trade mark](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Olaparib%20-%20Bio-X%20trade%20mark%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SCHEMBL426568](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SCHEMBL426568%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB [ORANGE BOOK]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20%5BORANGE%20BOOK%5D%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [CHEMBL521686](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CHEMBL521686%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [GTPL7519](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22GTPL7519%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [orb1304620](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22orb1304620%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SCHEMBL29352148](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SCHEMBL29352148%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SCHEMBL29392087](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SCHEMBL29392087%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BDBM27566](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BDBM27566%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [EX-A002](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EX-A002%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [GLXC-02796](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22GLXC-02796%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS3295I09](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3295I09%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS3426C03](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3426C03%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS3654G13](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3654G13%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS3746K07](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3746K07%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS3870H03](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3870H03%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS5079O07](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS5079O07%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HMS6019J08](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS6019J08%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [EBC-11384](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EBC-11384%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HY-10162R](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HY-10162R%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NSC747856](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC747856%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NSC753686](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC753686%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [s1060](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22s1060%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AKOS005145764](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AKOS005145764%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AC-7939](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AC-7939%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [CCG-264799](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CCG-264799%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [CS-0075](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CS-0075%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [DB09074](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22DB09074%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [EX-7210](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EX-7210%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [FO33122](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22FO33122%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NSC 747856](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC%20747856%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NSC-753686](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC-753686%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SB14617](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SB14617%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SS-4573](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SS-4573%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [AZD2281,Olaparib, KU-0059436](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AZD2281%2COlaparib%2C%20KU-0059436%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NCGC00238451-01](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00238451-01%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NCGC00238451-02](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00238451-02%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NCGC00238451-08](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00238451-08%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NCGC00238451-09](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00238451-09%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NCGC00238451-11](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00238451-11%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221(2H)-Phthalazinone%2C%204-%5B%5B3-%5B%5B4-(cyclopropylcarbonyl)-1-piperazinyl%5Dcarbonyl%5D-4-fluorophenyl%5Dmethyl%5D-%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BO164169](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BO164169%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BP-43641](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BP-43641%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [HY-10162](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HY-10162%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SMR004701291](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SMR004701291%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SY040527](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SY040527%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [OLAPARIB COMPONENT OF KEYLYNK-010](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22OLAPARIB%20COMPONENT%20OF%20KEYLYNK-010%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [NS00072449](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NS00072449%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [SW218142-2](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SW218142-2%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [D09730](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22D09730%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [EN300-7542225](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EN300-7542225%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [F043403](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22F043403%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Q7083106](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Q7083106%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BRD-K02113016-001-08-9](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K02113016-001-08-9%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BRD-K02113016-001-09-7](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K02113016-001-09-7%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BRD-K02113016-001-15-4](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K02113016-001-15-4%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [BRD-K02113016-001-19-6](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K02113016-001-19-6%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [Z2227698469](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Z2227698469%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-(3-{[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl}-4-fluorobenzyl)-1(2H)-phthalazinone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-(3-%7B%5B4-(Cyclopropylcarbonyl)-1-piperazinyl%5Dcarbonyl%7D-4-fluorobenzyl)-1(2H)-phthalazinone%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [(2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(2H)-Phthalazinone%2C%204-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [1021843-02-6](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221021843-02-6%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-(%7B3-%5B(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl%5D-4-fluorophenyl%7Dmethyl)-1%2C2-dihydrophthalazin-1-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [4-({3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl}methyl)phthalazin-1(2H)-one](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-(%7B3-%5B4-(Cyclopropanecarbonyl)piperazine-1-carbonyl%5D-4-fluorophenyl%7Dmethyl)phthalazin-1(2H)-one%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n*   [PIPERAZINE, 1-(CYCLOPROPYLCARBONYL)-4-(5-((3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PIPERAZINE%2C%201-(CYCLOPROPYLCARBONYL)-4-(5-((3%2C4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-%22[CompleteSynonym]%20AND%2023725625[StandardizedCID])\n\nPubChem\n\n3 Chemical and Physical Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-and-Physical-Properties&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 3.1 Computed Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Computed-Properties&fullscreen=true \"Open this section in a new browser window\")\n\nProperty Name\n\nProperty Value\n\nReference\n\nProperty Name\n\nMolecular Weight\n\nProperty Value\n\n434.5 g/mol\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2025.09.15)\n\nProperty Name\n\nXLogP3-AA\n\nProperty Value\n\n1.9 \n\nReference\n\nComputed by XLogP3 3.0 (PubChem release 2025.09.15)\n\nProperty Name\n\nHydrogen Bond Donor Count\n\nProperty Value\n\n1 \n\nReference\n\nComputed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)\n\nProperty Name\n\nHydrogen Bond Acceptor Count\n\nProperty Value\n\n5 \n\nReference\n\nComputed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)\n\nProperty Name\n\nRotatable Bond Count\n\nProperty Value\n\n4 \n\nReference\n\nComputed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)\n\nProperty Name\n\nExact Mass\n\nProperty Value\n\n434.17541877 Da\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2025.09.15)\n\nProperty Name\n\nMonoisotopic Mass\n\nProperty Value\n\n434.17541877 Da\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2025.09.15)\n\nProperty Name\n\nTopological Polar Surface Area\n\nProperty Value\n\n82.1 Å²\n\nReference\n\nComputed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)\n\nProperty Name\n\nHeavy Atom Count\n\nProperty Value\n\n32 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nFormal Charge\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nComplexity\n\nProperty Value\n\n790 \n\nReference\n\nComputed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)\n\nProperty Name\n\nIsotope Atom Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nDefined Atom Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nUndefined Atom Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nDefined Bond Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nUndefined Bond Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nCovalently-Bonded Unit Count\n\nProperty Value\n\n1 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nCompound Is Canonicalized\n\nProperty Value\n\nYes \n\nReference\n\nComputed by PubChem (release 2025.09.15)\n\nPubChem\n\n### 3.2 Experimental Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Experimental-Properties&fullscreen=true \"Open this section in a new browser window\")\n\n#### 3.2.1 Melting Point[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Melting-Point&fullscreen=true \"Open this section in a new browser window\")\n\n198 \n\n[https://www.fishersci.com/store/msds?partNumber=AC466292500&productDescription=OLAPARIB+250MG&vendorId=VN00032119&countryCode=US&language=en](https://www.fishersci.com/store/msds?partNumber=AC466292500&productDescription=OLAPARIB+250MG&vendorId=VN00032119&countryCode=US&language=en)\n\nDrugBank\n\n### 3.3 Chemical Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Classes&fullscreen=true \"Open this section in a new browser window\")\n\n#### 3.3.1 Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nPharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents \n\nS92 | FLUOROPHARMA | List of ~340 ATC classified fluoro-pharmaceuticals | [DOI:10.5281/zenodo.5979646](https://doi.org/DOI:10.5281/zenodo.5979646)\n\nNORMAN Suspect List Exchange\n\nPharmaceuticals -> Listed in ZINC15 \n\nS55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | [DOI:10.5281/zenodo.3247749](https://doi.org/DOI:10.5281/zenodo.3247749)\n\nNORMAN Suspect List Exchange\n\n##### 3.3.1.1 Human Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Human-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nBreast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Signal Transduction Inhibitors; PARP inhibitors \n\nDrugs and Lactation Database (LactMed)\n\nHuman drug -> Active ingredient (OLAPARIB)\n\nDrugs@FDA\n\nHuman drug -> Prescription; Discontinued \n\nDrugs@FDA\n\nHuman drugs -> Antineoplastic agents -> Human pharmacotherapeutic group -> EMA Drug Category \n\nEuropean Medicines Agency (EMA)\n\nPaediatric drug \n\nEuropean Medicines Agency (EMA)\n\nRare disease (orphan) drug \n\nEuropean Medicines Agency (EMA)\n\n4 Related Records[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Related-Records&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 4.1 Related Compounds with Annotation[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Related-Compounds-with-Annotation&fullscreen=true \"Open this section in a new browser window\")\n\nFollow these links to [do a live 2D search](https://pubchem.ncbi.nlm.nih.gov/#query=CID23725625%20structure&tab=similarity&sort=annothitcnt) or [do a live 3D search](https://pubchem.ncbi.nlm.nih.gov/#query=CID23725625%20structure&tab=similarity_3d&sort=annothitcnt) for this compound, sorted by annotation score. This section is deprecated (see [the neighbor discontinuation help page](https://pubchem.ncbi.nlm.nih.gov/docs/neighbor-discontinuation) for details), but these live search links provide equivalent functionality to the table that was previously shown here.\n\nPubChem\n\n### 4.2 Related Compounds[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Related-Compounds&fullscreen=true \"Open this section in a new browser window\")\n\nSame Connectivity Count\n\n[7](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/cids/JSON?cids_type=same_connectivity&list_return=redirect)\n\nSame Parent, Connectivity Count\n\n[18](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/cids/JSON?cids_type=same_parent_connectivity&list_return=redirect)\n\nSame Parent, Exact Count\n\n[12](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/cids/JSON?cids_type=same_parent&list_return=redirect)\n\nMixtures, Components, and Neutralized Forms Count\n\n[67](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/cids/JSON?cids_type=component&list_return=redirect)\n\nSimilar Compounds (2D)\n\n[View in PubChem Search](https://pubchem.ncbi.nlm.nih.gov/#query=CID23725625%20structure&tab=similarity)\n\nSimilar Conformers (3D)\n\n[View in PubChem Search](https://pubchem.ncbi.nlm.nih.gov/#query=CID23725625%20structure&tab=similarity_3d)\n\nPubChem\n\n### 4.3 Substances[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Substances&fullscreen=true \"Open this section in a new browser window\")\n\n#### 4.3.1 PubChem Reference Collection SID[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=PubChem-Reference-Collection-SID&fullscreen=true \"Open this section in a new browser window\")\n\n[483927292](https://pubchem.ncbi.nlm.nih.gov/substance/483927292)\n\nPubChem\n\n#### 4.3.2 Related Substances[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Related-Substances&fullscreen=true \"Open this section in a new browser window\")\n\nAll Count\n\n[333](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/sids/JSON?sids_type=all&list_return=redirect)\n\nSame Count\n\n[263](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/sids/JSON?sids_type=standardized&list_return=redirect)\n\nMixture Count\n\n[70](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/sids/JSON?sids_type=component&list_return=redirect)\n\nPubChem\n\n#### 4.3.3 Substances by Category[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Substances-by-Category&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 4.4 Entrez Crosslinks[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Entrez-Crosslinks&fullscreen=true \"Open this section in a new browser window\")\n\nPubMed Count\n\n[180](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&db=pccompound&cmd=Link&from_uid=23725625)\n\nProtein Structures Count\n\n[8](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_structure&db=pccompound&cmd=Link&from_uid=23725625)\n\nTaxonomy Count\n\n[3](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_taxonomy&db=pccompound&cmd=Link&from_uid=23725625)\n\nOMIM Count\n\n[1](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_omim&db=pccompound&cmd=Link&from_uid=23725625)\n\nGene Count\n\n[65](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_gene&db=pccompound&cmd=Link&from_uid=23725625)\n\nPubChem\n\n### 4.5 NCBI LinkOut[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NCBI-LinkOut&fullscreen=true \"Open this section in a new browser window\")\n\nNCBI\n\n5 Chemical Vendors[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Vendors&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nPubChem\n\n6 Drug and Medication Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-and-Medication-Information&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 6.1 Drug Indication[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-Indication&fullscreen=true \"Open this section in a new browser window\")\n\n**Ovarian cancer** Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy. Olaparib is indicated in combination with [bevacizumab] for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy. **Breast cancer** Olaparib is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious g_BRCA_m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious g_BRCA_m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR) positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. **Pancreatic cancer** Olaparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy regimen. **Prostate cancer** Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a hormone agent, such as [[enzalutamide](https://pubchem.ncbi.nlm.nih.gov/compound/enzalutamide)] or [[abiraterone](https://pubchem.ncbi.nlm.nih.gov/compound/abiraterone)]. It is also indicated in combination with [[abiraterone](https://pubchem.ncbi.nlm.nih.gov/compound/abiraterone)] and [[prednisone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisone)] or [[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone)] for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).\n\nDrugBank\n\nOvarian cancer Lynparza is indicated as monotherapy for the: maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy. maintenance treatment of adult patients with [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum) sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum) based chemotherapy. Lynparza in combination with bevacizumab is indicated for the: maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1). Breast cancer Lynparza is indicated as: monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 and 5. 1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a [taxane](https://pubchem.ncbi.nlm.nih.gov/compound/taxane) in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. Adenocarcinoma of the pancreasLynparza is indicated as: monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum) treatment within a first-line chemotherapy regimen. Prostate cancer Lynparza is indicated as: monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with [abiraterone](https://pubchem.ncbi.nlm.nih.gov/compound/abiraterone) and [prednisone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisone) or [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5. 1).\n\nEuropean Medicines Agency (EMA)\n\nTreatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) \n\nEuropean Medicines Agency (EMA)\n\nView More...\n\n### 6.2 LiverTox Summary[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=LiverTox-Summary&fullscreen=true \"Open this section in a new browser window\")\n\nOlaparib is a small molecule inhibitor of poly [ADP-ribose](https://pubchem.ncbi.nlm.nih.gov/compound/ADP-ribose) polymerase and is used as an antineoplastic agent in the therapy of refractory and advanced ovarian carcinoma. Olaparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy and has not been linked to instances of clinically apparent liver injury.\n\nLiverTox\n\n### 6.3 Drug Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nBreast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Signal Transduction Inhibitors; PARP inhibitors \n\nDrugs and Lactation Database (LactMed)\n\nAntineoplastic Agents \n\nLiverTox\n\n### 6.4 FDA Medication Guides[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Medication-Guides&fullscreen=true \"Open this section in a new browser window\")\n\nDrug\n\nActive Ingredient\n\nForm;Route\n\nCompany\n\nDate\n\nDrug\n\n[LYNPARZA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206162s011lbl.pdf#page=16)\n\nActive Ingredient\n\nOlaparib \n\nForm;Route\n\nCAPSULE;ORAL \n\nCompany\n\nASTRAZENECA \n\nDate\n\n9/27/2018 \n\nDrug\n\n[LYNPARZA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf#page=58)\n\nActive Ingredient\n\nOlaparib \n\nForm;Route\n\nTABLET;ORAL \n\nCompany\n\nASTRAZENECA \n\nDate\n\n7/10/2025 \n\nFDA Medication Guides\n\n### 6.5 FDA Approved Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Approved-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nDrugs@FDA\n\n### 6.6 FDA Orange Book[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Orange-Book&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Orange Book\n\n### 6.7 FDA National Drug Code Directory[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-National-Drug-Code-Directory&fullscreen=true \"Open this section in a new browser window\")\n\nNational Drug Code (NDC) Directory\n\n### 6.8 Drug Labels[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-Labels&fullscreen=true \"Open this section in a new browser window\")\n\nDrug and label\n\nDailyMed\n\nView More...\n\n### 6.9 Cancer Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Cancer-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nDrug Name\n\nLynparza (Olaparib) \n\nBrand Name(s)\n\nLynparza \n\nFDA Approved\n\nYes \n\nDrug Use\n\nOlaparib is approved to treat:\n\n• Breast cancer that is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. Olaparib is used after surgery in adults with:\n\n• high-risk early-stage breast cancer that has been treated with chemotherapy before or after surgery\n\n• metastatic cancer that has been treated with chemotherapy before or after the cancer spread\n\n• Ovarian epithelial,fallopian tube, or primary peritoneal cancer. Olaparib is used as maintenance therapy in adults who are having a complete or partial response to [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum) chemotherapy. It is used:\n\n• as the first maintenance therapy in patients with advanced cancer that has certain germline or somatic mutations in the BRCA1 or BRCA2 gene\n\n• with bevacizumab as the first maintenance therapy in patients with advanced cancer that has genomic instability and/or certain germline or somatic mutations in the BRCA1 or BRCA2 gene\n\n• in patients with recurrent cancer\n\n• Pancreatic cancer. Olaparib is used as maintenance therapy in adults with metastatic cancer that has not progressed after first-line therapy with [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum) chemotherapy and has certain germline mutations in the BRCA1 or BRCA2 gene.\n\n• Prostate cancer that has spread to other parts of the body and is castrate resistant (has not responded to treatments that lower [testosterone](https://pubchem.ncbi.nlm.nih.gov/compound/testosterone) levels). Olaparib is used:\n\n• alone in adults with germline or somatic mutations in certain genes involved in the homologous recombination repair pathway whose cancer has gotten worse after treatment with [enzalutamide](https://pubchem.ncbi.nlm.nih.gov/compound/enzalutamide) or [abiraterone](https://pubchem.ncbi.nlm.nih.gov/compound/abiraterone)\n\n• with [abiraterone](https://pubchem.ncbi.nlm.nih.gov/compound/abiraterone) and [prednisone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisone) or [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) in adults with certain mutations in the BRCA1 or BRCA2 gene\n\nOlaparib is also being studied in the treatment of other types of cancer.\n\nNCI Cancer Drugs\n\n### 6.10 Clinical Trials[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Clinical-Trials&fullscreen=true \"Open this section in a new browser window\")\n\n#### 6.10.1 ClinicalTrials.gov[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ClinicalTrials-gov&fullscreen=true \"Open this section in a new browser window\")\n\nClinicalTrials.gov\n\n#### 6.10.2 EU Clinical Trials Register[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=EU-Clinical-Trials-Register&fullscreen=true \"Open this section in a new browser window\")\n\nEU Clinical Trials Register\n\n#### 6.10.3 NIPH Clinical Trials Search of Japan[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NIPH-Clinical-Trials-Search-of-Japan&fullscreen=true \"Open this section in a new browser window\")\n\nNIPH Clinical Trials Search of Japan\n\n### 6.11 EMA Drug Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=EMA-Drug-Information&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 3 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=EMA-Drug-Information&fullscreen=true \"Open this section in a new browser window\")\n\nMedicine\n\n[Lynparza](https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza)\n\nCategory\n\nHuman drugs \n\nTherapeutic area\n\nOvarian Neoplasms \n\nActive Substance\n\nOlaparib \n\nINN/Common name\n\nolaparib \n\nPharmacotherapeutic Classes\n\nAntineoplastic agents \n\nStatus\n\nThis medicine is authorized for use in the European Union \n\nCompany\n\nAstraZeneca AB \n\nMarket Date\n\n2014-12-16 \n\nEuropean Medicines Agency (EMA)\n\n2 of 3 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=EMA-Drug-Information&fullscreen=true \"Open this section in a new browser window\")\n\nType\n\nPaediatric investigation \n\nActive Substance\n\n[Olaparib](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002269-pip01-17-m01)\n\nTherapeutic Area\n\nOncology \n\nDrug Form\n\nCapsule, hard, Film-coated tablet \n\nAdministration Route\n\nOral use \n\nDecision Type\n\nPM: decision on the application for modification of an agreed PIP \n\nDecision Date\n\n2020-07-15 \n\nEuropean Medicines Agency (EMA)\n\n### 6.12 Japan PMDA Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Japan-PMDA-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nBrand Name\n\nLynparza \n\nNon-proprietary Name\n\nOlaparib \n\nApproval Note\n\nPartial Change Approval \n\nApproval Date\n\nAugust 2023 \n\nReview Document\n\n[PDF](https://www.pmda.go.jp/files/000269956.pdf)\n\nJapan Pharmaceuticals and Medical Devices Agency (PMDA)\n\n7 Pharmacology and Biochemistry[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Pharmacology-and-Biochemistry&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 7.1 Pharmacodynamics[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Pharmacodynamics&fullscreen=true \"Open this section in a new browser window\")\n\nOlaparib is a cytotoxic and anti-tumour agent. Olaparib inhibits the growth of selective tumour cell lines _in vitro_ and decreases tumour growth in mouse xenograft models of human cancer, both as monotherapy or following [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based chemotherapy. The drug exerts anti-tumour effects in cell lines and mouse tumour models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum) response. In preclinical models of cancer, olaparib demonstrated anti-tumour activity when used alone, in combination with chemotherapeutic agents, or radiotherapy. Olaparib can act as a chemosensitizer to potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents such as alkylating agents and [platinum](https://pubchem.ncbi.nlm.nih.gov/element/Platinum)-based drugs. It can also act as a radiosensitizer by preventing PARP-mediated DNA repair.\n\nDrugBank\n\n### 7.2 MeSH Pharmacological Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=MeSH-Pharmacological-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nAntineoplastic Agents\n\nSubstances that inhibit or prevent the proliferation of NEOPLASMS. \n\nMedical Subject Headings (MeSH)\n\nPoly(ADP-ribose) Polymerase Inhibitors\n\nChemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. \n\nMedical Subject Headings (MeSH)\n\n### 7.3 FDA Pharmacological Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Pharmacological-Classification&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 2 items\n\nFDA UNII\n\nWOH1JD9AR8 \n\nActive Moiety\n\nOLAPARIB \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Poly(ADP-Ribose) Polymerase Inhibitor \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Poly(ADP-Ribose) Polymerase Inhibitors \n\nFDA Pharmacology Summary\n\nOlaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.\n\nFDA Pharm Classes\n\n2 of 2 items\n\nNon-Proprietary Name\n\nOLAPARIB \n\nPharmacological Classes\n\nPoly(ADP-Ribose) Polymerase Inhibitor [EPC]; Poly(ADP-Ribose) Polymerase Inhibitors [MoA] \n\nNational Drug Code (NDC) Directory\n\n### 7.4 ATC Code[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ATC-Code&fullscreen=true \"Open this section in a new browser window\")\n\nL01XK01 \n\nEuropean Medicines Agency (EMA)\n\n[L](https://atcddd.fhi.no/atc_ddd_index/?code=L) - Antineoplastic and immunomodulating agents\n\n[L01](https://atcddd.fhi.no/atc_ddd_index/?code=L01) - Antineoplastic agents\n\n[L01X](https://atcddd.fhi.no/atc_ddd_index/?code=L01X) - Other antineoplastic agents\n\n[L01XK](https://atcddd.fhi.no/atc_ddd_index/?code=L01XK) - Poly (adp-ribose) polymerase (parp) inhibitors\n\n[L01XK01](https://atcddd.fhi.no/atc_ddd_index/?code=L01XK01) - Olaparib\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\nATCvet Code\n\n[QL](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL) - Antineoplastic and immunomodulating agents\n\n[QL01](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01) - Antineoplastic agents\n\n[QL01X](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01X) - Other antineoplastic agents\n\n[QL01XK](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01XK) - Poly (adp-ribose) polymerase (parp) inhibitors\n\n[QL01XK01](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01XK01) - Olaparib\n\nWHO ATCvet - Classification of Veterinary Medicines\n\n### 7.5 Absorption, Distribution and Excretion[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Absorption-Distribution-and-Excretion&fullscreen=true \"Open this section in a new browser window\")\n\nAbsorption\n\nFollowing oral administration, olaparib is rapidly absorbed. After administration of a single 300 mg dose of olaparib, the mean (CV%) C max was 5.4 μg/mL (32%) and AUC was 39.2 μg x h/mL (44%). The steady state C max and AUC following a dose of 300 mg twice daily was 7.6 μg/mL (35%) and 49.2 μg x h/mL (44%), respectively. T max is 1.5 hours. A high-fat and high-calorie meal may delay T max, but does not significantly alter the extent of olaparib absorption.\n\nDrugBank\n\nRoute of Elimination\n\nFollowing a single dose of radiolabeled olaparib, 86% of the dosed radioactivity was recovered within a seven-day collection period, mostly in the form of metabolites. About 44% of the drug was excreted via the urine and 42% of the dose was excreted via the feces. Following an oral dose of radiolabeled olaparib to female patients, the unchanged drug accounted for 15% and 6% of the radioactivity in urine and feces, respectively.\n\nDrugBank\n\nVolume of Distribution\n\nThe mean (± standard deviation) apparent volume of distribution of olaparib is 158 ± 136 L following a single 300 mg dose.\n\nDrugBank\n\nClearance\n\nFollowing a single oral dose in patients with cancer, the mean apparent plasma clearance was 4.55 L/h. \n\nDrugBank\n\n### 7.6 Protein Binding[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Protein-Binding&fullscreen=true \"Open this section in a new browser window\")\n\nThe protein binding of olaparib is approximately 82% _in vitro_. In solutions of purified proteins, the olaparib fraction bound to albumin was approximately 56% and the fraction bound to alpha-1 acid glycoprotein was 29%.\n\nDrugBank\n\n### 7.7 Metabolism / Metabolites[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Metabolism-Metabolites&fullscreen=true \"Open this section in a new browser window\")\n\nOlaparib is metabolized by cytochrome P450 (CYP) 3A4/5 _in vitro_. Following an oral dose of radiolabeled olaparib to female patients, unchanged olaparib accounted for 70% of the circulating radioactivity in plasma. Olaparib undergoes oxidation reactions as well as subsequent glucuronide or [sulfate](https://pubchem.ncbi.nlm.nih.gov/compound/sulfate) conjugation. In humans, olaparib can also undergo hydrolysis, hydroxylation, and dehydrogenation. While up to 37 metabolites of olaparib were detected in plasma, urine, and feces, the majority of metabolites represent less than 1% of the total administered dose and they have not been fully characterized. The major circulating metabolites are a ring-opened piperazin-3-ol moiety and two mono-oxygenated metabolites. The pharmacodynamic activity of the metabolites is unknown.\n\nDrugBank\n\n### 7.8 Biological Half-Life[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Biological-Half-Life&fullscreen=true \"Open this section in a new browser window\")\n\nFollowing a single oral dose in patients with cancer, the mean terminal half-life was 6.10 hours. \n\nDrugBank\n\n### 7.9 Mechanism of Action[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Mechanism-of-Action&fullscreen=true \"Open this section in a new browser window\")\n\nPoly(ADP-ribose) polymerases (PARPs) are multifunctional enzymes comprising 17 members. They are involved in essential cellular functions, such as DNA transcription and DNA repair. PARPs recognize and repair cellular DNA damage, such as single-strand breaks (SSBs) and double-strand breaks (DSBs). Different DNA repair pathways exist to repair these DNA damages, including the base excision repair (BER) pathway for SSBs and BRCA-dependent homologous recombination for DSBs. Olaparib is a PARP inhibitor: while it acts on PARP1, PARP2, and PARP3, olaparib is a more selective competitive inhibitor of [NAD+](https://pubchem.ncbi.nlm.nih.gov/compound/NAD%2B) at the catalytic site of PARP1 and PARP2. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of DSBs, which is the most toxic form of DNA damage. While BRCA-dependent homologous recombination can repair DSBs in normal cells, this repair pathway is defective in cells with BRCA1/2 mutations, such as certain tumour cells. Inhibition of PARP in cancer cells with BRCA mutations leads to genomic instability and apoptotic cell death. This end result is also referred to as synthetic lethality, a phenomenon where the combination of two defects - inhibition of PARP activity and loss of DSB repair by HR - that are otherwise benign when alone, lead to detrimental results. _In vitro_ studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.\n\nDrugBank\n\n8 Use and Manufacturing[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Use-and-Manufacturing&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 8.1 Uses[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Uses&fullscreen=true \"Open this section in a new browser window\")\n\n#### 8.1.1 Use Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Use-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nHuman drugs -> Antineoplastic agents -> Human pharmacotherapeutic group -> EMA Drug Category \n\nEuropean Medicines Agency (EMA)\n\nHuman Drugs -> EU pediatric investigation plans \n\nEuropean Medicines Agency (EMA)\n\nHuman drugs -> Rare disease (orphan) \n\nEuropean Medicines Agency (EMA)\n\nHuman Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients \n\nFDA Orange Book\n\n9 Safety and Hazards[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Safety-and-Hazards&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 9.1 Hazards Identification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Hazards-Identification&fullscreen=true \"Open this section in a new browser window\")\n\n#### 9.1.1 GHS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=GHS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nPictogram(s)\n\n![Image 8: Acute Toxic](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS06.svg)\n\n![Image 9: Health Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg)\n\n![Image 10: Environmental Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS09.svg)\n\nSignal\n\nDanger\n\nGHS Hazard Statements\n\nH301 (92.5%): Toxic if swallowed [Danger Acute toxicity, oral]\n\nH341 (77.5%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]\n\nH360 (12.5%): May damage fertility or the unborn child [Danger Reproductive toxicity]\n\nH360D (80%): May damage the unborn child [Danger Reproductive toxicity]\n\nH372 (90%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]\n\nH411 (77.5%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]\n\nPrecautionary Statement Codes\n\n[P203](https://pubchem.ncbi.nlm.nih.gov/ghs/#P203), [P260](https://pubchem.ncbi.nlm.nih.gov/ghs/#P260), [P264](https://pubchem.ncbi.nlm.nih.gov/ghs/#P264), [P270](https://pubchem.ncbi.nlm.nih.gov/ghs/#P270), [P273](https://pubchem.ncbi.nlm.nih.gov/ghs/#P273), [P280](https://pubchem.ncbi.nlm.nih.gov/ghs/#P280), [P301+P316](https://pubchem.ncbi.nlm.nih.gov/ghs/#P301+P316), [P318](https://pubchem.ncbi.nlm.nih.gov/ghs/#P318), [P319](https://pubchem.ncbi.nlm.nih.gov/ghs/#P319), [P321](https://pubchem.ncbi.nlm.nih.gov/ghs/#P321), [P330](https://pubchem.ncbi.nlm.nih.gov/ghs/#P330), [P391](https://pubchem.ncbi.nlm.nih.gov/ghs/#P391), [P405](https://pubchem.ncbi.nlm.nih.gov/ghs/#P405), and [P501](https://pubchem.ncbi.nlm.nih.gov/ghs/#P501)\n\nECHA C&L Notifications Summary\n\n_Aggregated GHS information provided per 40 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies._\n\n_Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit [ECHA C&L website.](https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/175706)_\n\nEuropean Chemicals Agency (ECHA)\n\n#### 9.1.2 Hazard Classes and Categories[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Hazard-Classes-and-Categories&fullscreen=true \"Open this section in a new browser window\")\n\nAcute Tox. 3 (92.5%)\n\nMuta. 2 (77.5%)\n\nRepr. 1B (12.5%)\n\nRepr. 1B (80%)\n\nSTOT RE 1 (90%)\n\nAquatic Chronic 2 (77.5%)\n\nEuropean Chemicals Agency (ECHA)\n\n10 Toxicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Toxicity&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------\n\n### 10.1 Toxicological Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Toxicological-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 10.1.1 Hepatotoxicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Hepatotoxicity&fullscreen=true \"Open this section in a new browser window\")\n\nIn large clinical trials of olaparib, abnormalities in routine liver tests were uncommon with serum aminotransferase elevations occurring in 4% of patients and values above 5 times the upper limit of normal (ULN) in 1% or less. In trials of olaparib in patients with various advanced solid tumors there were no reports of hepatitis with jaundice or liver failure. Subsequent to its approval and more widescale use, there have been no published reports of clinically apparent liver injury attributed to olaparib.\n\nLikelihood score: E (unlikely cause of clinically apparent liver injury).\n\nLiverTox\n\n#### 10.1.2 Drug Induced Liver Injury[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-Induced-Liver-Injury&fullscreen=true \"Open this section in a new browser window\")\n\nDataset\n\nDrug Induced Liver Injury Rank (DILIrank 2.0) \n\nCompound\n\nOlaparib \n\nvDILI-Concern\n\nv Less-DILI-concern\n\nSeverity Class\n\n0 \n\nLabel Section\n\nNo match \n\nReferences\n\n[DOI:10.1016/j.drudis.2016.02.015](https://doi.org/10.1016/j.drudis.2016.02.015)\n\nFDA Liver Toxicity Knowledge Base (LTKB)\n\n#### 10.1.3 Effects During Pregnancy and Lactation[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Effects-During-Pregnancy-and-Lactation&fullscreen=true \"Open this section in a new browser window\")\n\n◉ Summary of Use during Lactation\n\nNo information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.\n\n◉ Effects in Breastfed Infants\n\nRelevant published information was not found as of the revision date.\n\n◉ Effects on Lactation and Breastmilk\n\nRelevant published information was not found as of the revision date.\n\nDrugs and Lactation Database (LactMed)\n\n11 Associated Disorders and Diseases[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Associated-Disorders-and-Diseases&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nComparative Toxicogenomics Database (CTD); Open Targets; Therapeutic Target Database (TTD)\n\n12 Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Literature&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 12.1 Consolidated References[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Consolidated-References&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 12.2 NLM Curated PubMed Citations[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NLM-Curated-PubMed-Citations&fullscreen=true \"Open this section in a new browser window\")\n\nMedical Subject Headings (MeSH)\n\n### 12.3 Springer Nature References[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Springer-Nature-References&fullscreen=true \"Open this section in a new browser window\")\n\nSpringer Nature\n\n### 12.4 Thieme References[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Thieme-References&fullscreen=true \"Open this section in a new browser window\")\n\nThieme Chemistry\n\n### 12.5 Wiley References[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Wiley-References&fullscreen=true \"Open this section in a new browser window\")\n\nWiley\n\n### 12.6 Nature Journal References[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Nature-Journal-References&fullscreen=true \"Open this section in a new browser window\")\n\n[Dubach et al. Quantitating drug-target engagement in single cells in vitro and in vivo. Nature Chemical Biology, doi: 10.1038/nchembio.2248, published online 5 December 2016](http://dx.doi.org/10.1038/nchembio.2248)\n\nNature Chemical Biology\n\n### 12.7 Chemical Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 12.8 Chemical-Gene Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Gene-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 12.9 Chemical-Disease Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Disease-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 12.10 Chemical-Organism Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Organism-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n13 Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Patents&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------\n\n*   [US8859562](https://pubchem.ncbi.nlm.nih.gov/patent/US8859562)\n*   [US8912187](https://pubchem.ncbi.nlm.nih.gov/patent/US8912187)\n*   [US8143241](https://pubchem.ncbi.nlm.nih.gov/patent/US8143241)\n*   [US7449464](https://pubchem.ncbi.nlm.nih.gov/patent/US7449464)\n*   [US8247416](https://pubchem.ncbi.nlm.nih.gov/patent/US8247416)\n*   [US7151102](https://pubchem.ncbi.nlm.nih.gov/patent/US7151102)\n*   [US7981889](https://pubchem.ncbi.nlm.nih.gov/patent/US7981889)\n*   [US8475842](https://pubchem.ncbi.nlm.nih.gov/patent/US8475842)\n*   [US9566276](https://pubchem.ncbi.nlm.nih.gov/patent/US9566276)\n*   [US8071579](https://pubchem.ncbi.nlm.nih.gov/patent/US8071579)\n*   [US9169235](https://pubchem.ncbi.nlm.nih.gov/patent/US9169235)\n*   [US11633396](https://pubchem.ncbi.nlm.nih.gov/patent/US11633396)\n*   [US11970530](https://pubchem.ncbi.nlm.nih.gov/patent/US11970530)\n*   [US11975001](https://pubchem.ncbi.nlm.nih.gov/patent/US11975001)\n*   [US12048695](https://pubchem.ncbi.nlm.nih.gov/patent/US12048695)\n*   [US12144810](https://pubchem.ncbi.nlm.nih.gov/patent/US12144810)\n*   [US12178816](https://pubchem.ncbi.nlm.nih.gov/patent/US12178816)\n\nDrugBank\n\n### 13.1 Depositor-Supplied Patent Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Depositor-Supplied-Patent-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n[Link to all deposited patent identifiers](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/23725625/xrefs/PatentID/TXT)\n\nPubChem\n\n### 13.2 WIPO PATENTSCOPE[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=WIPO-PATENTSCOPE&fullscreen=true \"Open this section in a new browser window\")\n\nPatents are available for this chemical structure:\n\n[https://patentscope.wipo.int/search/en/result.jsf?inchikey=FDLYAMZZIXQODN-UHFFFAOYSA-N](https://patentscope.wipo.int/search/en/result.jsf?inchikey=FDLYAMZZIXQODN-UHFFFAOYSA-N)\n\nPATENTSCOPE (WIPO)\n\n### 13.3 FDA Orange Book Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Orange-Book-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Orange Book\n\n### 13.4 Chemical Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 13.5 Chemical-Disease Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Disease-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 13.6 Chemical-Gene Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Gene-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 13.7 Chemical-Organism Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Organism-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n14 Interactions and Pathways[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Interactions-and-Pathways&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 14.1 Protein Bound 3D Structures[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Protein-Bound-3D-Structures&fullscreen=true \"Open this section in a new browser window\")\n\nRCSB Protein Data Bank (RCSB PDB)\n\n[View 8 proteins in NCBI Structure](https://www.ncbi.nlm.nih.gov/structure?cmd=Link&LinkName=pccompound_structure&from_uid=23725625)\n\nPubChem\n\n#### 14.1.1 Ligands from Protein Bound 3D Structures[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Ligands-from-Protein-Bound-3D-Structures&fullscreen=true \"Open this section in a new browser window\")\n\nPDBe Ligand Code\n\n[09L](http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/09L)\n\nPDBe Structure Code\n\n[3U9Y](http://www.ebi.ac.uk/pdbe/entry/pdb/3U9Y)\n\nPDBe Conformer\n\nProtein Data Bank in Europe (PDBe)\n\n### 14.2 Chemical-Target Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemical-Target-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nBindingDB; Chemical Probes Portal; Comparative Toxicogenomics Database (CTD); Drug Gene Interaction database (DGIdb); IUPHAR/BPS Guide to PHARMACOLOGY\n\nDrugBank\n\n### 14.3 Drug-Drug Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-Drug-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nDrugBank\n\n### 14.4 Drug-Food Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Drug-Food-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\n*   Avoid grapefruit products. Grapefruit inhibits the CYP3A metabolism of olaparib, which may increase its serum concentration.\n*   Avoid St. John's Wort. This herb induces the CYP3A metabolism of olaparib and may reduce its serum concentration.\n*   Take with or without food. Food does not significantly alter the extent of olaparib absorption.\n\nDrugBank\n\n### 14.5 Pathways[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Pathways&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n15 Biological Test Results[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Biological-Test-Results&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 15.1 BioAssay Results[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=BioAssay-Results&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n16 Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Classification&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 16.1 MeSH Tree[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=MeSH-Tree&fullscreen=true \"Open this section in a new browser window\")\n\nMedical Subject Headings (MeSH)\n\n### 16.2 NCI Thesaurus Tree[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NCI-Thesaurus-Tree&fullscreen=true \"Open this section in a new browser window\")\n\nNCI Thesaurus (NCIt)\n\n### 16.3 ChEBI Ontology[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ChEBI-Ontology&fullscreen=true \"Open this section in a new browser window\")\n\nChEBI\n\n### 16.4 KEGG: Drug[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-Drug&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 16.5 KEGG: USP[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-USP&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 16.6 KEGG: ATC[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-ATC&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 16.7 KEGG: Target-based Classification of Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-Target-based-Classification-of-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 16.8 KEGG: Drug Groups[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-Drug-Groups&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 16.9 KEGG: Drug Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=KEGG-Drug-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 16.10 WHO ATC Classification System[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=WHO-ATC-Classification-System&fullscreen=true \"Open this section in a new browser window\")\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\n### 16.11 FDA Pharm Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Pharm-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Pharm Classes\n\n### 16.12 ChemIDplus[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ChemIDplus&fullscreen=true \"Open this section in a new browser window\")\n\nChemIDplus\n\n### 16.13 IUPHAR / BPS Guide to PHARMACOLOGY Target Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=IUPHAR-BPS-Guide-to-PHARMACOLOGY-Target-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nIUPHAR/BPS Guide to PHARMACOLOGY\n\n### 16.14 ChEMBL Target Tree[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ChEMBL-Target-Tree&fullscreen=true \"Open this section in a new browser window\")\n\nChEMBL\n\n### 16.15 UN GHS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=UN-GHS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nGHS Classification (UNECE)\n\n### 16.16 NORMAN Suspect List Exchange Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=NORMAN-Suspect-List-Exchange-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nNORMAN Suspect List Exchange\n\n### 16.17 EPA DSSTox Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=EPA-DSSTox-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nEPA DSSTox\n\n### 16.18 FDA Drug Type and Pharmacologic Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Drug-Type-and-Pharmacologic-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nNational Drug Code (NDC) Directory\n\n### 16.19 PFAS and Fluorinated Organic Compounds in PubChem[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=PFAS-and-Fluorinated-Organic-Compounds-in-PubChem&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 16.20 MolGenie Organic Chemistry Ontology[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=MolGenie-Organic-Chemistry-Ontology&fullscreen=true \"Open this section in a new browser window\")\n\nMolGenie\n\n### 16.21 Chemicals in PubChem from Regulatory Sources[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Chemicals-in-PubChem-from-Regulatory-Sources&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 16.22 ATCvet Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=ATCvet-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nWHO ATCvet - Classification of Veterinary Medicines\n\n### 16.23 FDA Liver Toxicity Knowledge Base (LTKB)[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=FDA-Liver-Toxicity-Knowledge-Base-LTKB&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Liver Toxicity Knowledge Base (LTKB)\n\n17 Information Sources[](https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib#section=Information-Sources&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nFilter by Source \n\n1.   [BindingDB](https://pubchem.ncbi.nlm.nih.gov/source/BindingDB)LICENSE All data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License ([https://creativecommons.org/licenses/by/3.0/us/](https://creativecommons.org/licenses/by/3.0/us/)).  [https://www.bindingdb.org/rwd/bind/info.jsp](https://www.bindingdb.org/rwd/bind/info.jsp) 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one [https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=27566](https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=27566) \n2.   [Chemical Probes Portal](https://pubchem.ncbi.nlm.nih.gov/source/Chemical%20Probes%20Portal)Olaparib [https://www.chemicalprobes.org/olaparib](https://www.chemicalprobes.org/olaparib) \n3.   [Comparative Toxicogenomics Database (CTD)](https://pubchem.ncbi.nlm.nih.gov/source/Comparative%20Toxicogenomics%20Database%20(CTD))LICENSE It is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University. [http://ctdbase.org/about/legal.jsp](http://ctdbase.org/about/legal.jsp) olaparib [https://ctdbase.org/detail.go?type=chem&acc=C531550](https://ctdbase.org/detail.go?type=chem&acc=C531550) \n4.   [Drug Gene Interaction database (DGIdb)](https://pubchem.ncbi.nlm.nih.gov/source/Drug%20Gene%20Interaction%20database%20(DGIdb))LICENSE The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section. [http://www.dgidb.org/downloads](http://www.dgidb.org/downloads) OLAPARIB [https://www.dgidb.org/drugs/rxcui:1597582](https://www.dgidb.org/drugs/rxcui:1597582) \n5.   [DrugBank](https://pubchem.ncbi.nlm.nih.gov/source/DrugBank)LICENSE Creative Common's Attribution-NonCommercial 4.0 International License ([http://creativecommons.org/licenses/by-nc/4.0/legalcode](http://creativecommons.org/licenses/by-nc/4.0/legalcode))  [https://www.drugbank.ca/legal/terms_of_use](https://www.drugbank.ca/legal/terms_of_use) Olaparib [https://www.drugbank.ca/drugs/DB09074](https://www.drugbank.ca/drugs/DB09074) \n6.   [IUPHAR/BPS Guide to PHARMACOLOGY](https://pubchem.ncbi.nlm.nih.gov/source/IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY)LICENSE The Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) [https://opendatacommons.org/licenses/odbl/](https://opendatacommons.org/licenses/odbl/). Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License ([http://creativecommons.org/licenses/by-sa/4.0/](http://creativecommons.org/licenses/by-sa/4.0/))  [https://www.guidetopharmacology.org/about.jsp#license](https://www.guidetopharmacology.org/about.jsp#license) olaparib [https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7519](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7519) Guide to Pharmacology Target Classification [https://www.guidetopharmacology.org/targets.jsp](https://www.guidetopharmacology.org/targets.jsp) \n7.   [CAS Common Chemistry](https://pubchem.ncbi.nlm.nih.gov/source/CAS%20Common%20Chemistry)LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. [https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/) Olaparib [https://commonchemistry.cas.org/detail?cas_rn=763113-22-0](https://commonchemistry.cas.org/detail?cas_rn=763113-22-0) \n8.   [ChemIDplus](https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Olaparib [USAN:INN] [https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0763113220](https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0763113220) ChemIDplus Chemical Information Classification [https://pubchem.ncbi.nlm.nih.gov/source/chemidplus](https://pubchem.ncbi.nlm.nih.gov/source/chemidplus) \n9.   [DTP/NCI](https://pubchem.ncbi.nlm.nih.gov/source/DTP/NCI)LICENSE Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) Olaparib [https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=747856](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=747856) Olaparib [https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=753686](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=753686) \n10.   [EPA DSSTox](https://pubchem.ncbi.nlm.nih.gov/source/EPA%20DSSTox)LICENSE [https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources](https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources) Olaparib [https://comptox.epa.gov/dashboard/DTXSID60917988](https://comptox.epa.gov/dashboard/DTXSID60917988) CompTox Chemicals Dashboard Chemical Lists [https://comptox.epa.gov/dashboard/chemical-lists/](https://comptox.epa.gov/dashboard/chemical-lists/) \n11.   [European Chemicals Agency (ECHA)](https://pubchem.ncbi.nlm.nih.gov/source/European%20Chemicals%20Agency%20(ECHA))LICENSE Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, [http://echa.europa.eu/](http://echa.europa.eu/)\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.  [https://echa.europa.eu/web/guest/legal-notice](https://echa.europa.eu/web/guest/legal-notice) 4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl) -4-fluorophenyl]methyl(2H)phthalazin-1-one [https://chem.echa.europa.eu/100.170.811](https://chem.echa.europa.eu/100.170.811) 4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl) -4-fluorophenyl]methyl(2H)phthalazin-1-one (EC: 642-941-5) [https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/175706](https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/175706) \n12.   [FDA Global Substance Registration System (GSRS)](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Global%20Substance%20Registration%20System%20(GSRS))LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) Olaparib [https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WOH1JD9AR8](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WOH1JD9AR8) \n13.   [ChEBI](https://pubchem.ncbi.nlm.nih.gov/source/ChEBI)Olaparib [https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:83766](https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:83766) ChEBI Ontology [https://www.ebi.ac.uk/chebi/](https://www.ebi.ac.uk/chebi/) \n14.   [FDA Pharm Classes](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Pharm%20Classes)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) OLAPARIB [https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm](https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm) FDA Pharmacological Classification [https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class](https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class) \n15.   [LiverTox](https://pubchem.ncbi.nlm.nih.gov/source/LiverTox)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Olaparib [https://www.ncbi.nlm.nih.gov/books/n/livertox/Olaparib/](https://www.ncbi.nlm.nih.gov/books/n/livertox/Olaparib/) \n16.   [NCI Thesaurus (NCIt)](https://pubchem.ncbi.nlm.nih.gov/source/NCI%20Thesaurus%20(NCIt))LICENSE Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71721](https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71721) NCI Thesaurus [https://ncit.nci.nih.gov](https://ncit.nci.nih.gov/) \n17.   [Open Targets](https://pubchem.ncbi.nlm.nih.gov/source/Open%20Targets)LICENSE Datasets generated by the Open Targets Platform are freely available for download. [https://platform-docs.opentargets.org/licence](https://platform-docs.opentargets.org/licence) OLAPARIB [https://platform.opentargets.org/drug/CHEMBL521686](https://platform.opentargets.org/drug/CHEMBL521686) \n18.   [ChEMBL](https://pubchem.ncbi.nlm.nih.gov/source/ChEMBL)LICENSE Access to the web interface of ChEMBL is made under the EBI's Terms of Use ([http://www.ebi.ac.uk/Information/termsofuse.html](http://www.ebi.ac.uk/Information/termsofuse.html)). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License ([http://creativecommons.org/licenses/by-sa/3.0/](http://creativecommons.org/licenses/by-sa/3.0/)).  [http://www.ebi.ac.uk/Information/termsofuse.html](http://www.ebi.ac.uk/Information/termsofuse.html) [https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL521686](https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL521686) ChEMBL Protein Target Tree [https://www.ebi.ac.uk/chembl/g/#browse/targets](https://www.ebi.ac.uk/chembl/g/#browse/targets) \n19.   [ClinicalTrials.gov](https://pubchem.ncbi.nlm.nih.gov/source/ClinicalTrials.gov)LICENSE The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use. [https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use](https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use) [https://clinicaltrials.gov/](https://clinicaltrials.gov/) \n20.   [Therapeutic Target Database (TTD)](https://pubchem.ncbi.nlm.nih.gov/source/Therapeutic%20Target%20Database%20(TTD))Olaparib [https://ttd.idrblab.cn/data/drug/details/D0J9HW](https://ttd.idrblab.cn/data/drug/details/D0J9HW) \n21.   [DailyMed](https://pubchem.ncbi.nlm.nih.gov/source/DailyMed)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) OLAPARIB [https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OLAPARIB](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OLAPARIB) \n22.   [European Medicines Agency (EMA)](https://pubchem.ncbi.nlm.nih.gov/source/European%20Medicines%20Agency%20(EMA))LICENSE Information on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices. [https://www.ema.europa.eu/en/about-us/about-website/legal-notice](https://www.ema.europa.eu/en/about-us/about-website/legal-notice) Lynparza (EMEA/H/C/003726) [https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza](https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza) Olaparib (P/0250/2020) [https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002269-pip01-17-m01](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002269-pip01-17-m01) Olaparib (EU/3/07/501) [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-501](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-501) \n23.   [Drugs and Lactation Database (LactMed)](https://pubchem.ncbi.nlm.nih.gov/source/Drugs%20and%20Lactation%20Database%20(LactMed))LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Olaparib [https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM1297/](https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM1297/) \n24.   [Drugs@FDA](https://pubchem.ncbi.nlm.nih.gov/source/Drugs@FDA)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) OLAPARIB [https://www.accessdata.fda.gov/scripts/cder/daf/](https://www.accessdata.fda.gov/scripts/cder/daf/) \n25.   [EU Clinical Trials Register](https://pubchem.ncbi.nlm.nih.gov/source/EU%20Clinical%20Trials%20Register)[https://www.clinicaltrialsregister.eu/](https://www.clinicaltrialsregister.eu/) \n26.   [FDA Orange Book](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Orange%20Book)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) OLAPARIB [https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book](https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book) \n27.   [WHO Anatomical Therapeutic Chemical (ATC) Classification](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20Anatomical%20Therapeutic%20Chemical%20(ATC)%20Classification)LICENSE Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. [https://www.whocc.no/copyright_disclaimer/](https://www.whocc.no/copyright_disclaimer/) Olaparib [https://atcddd.fhi.no/atc_ddd_index/?code=L01XK01](https://atcddd.fhi.no/atc_ddd_index/?code=L01XK01) ATC Classification [https://atcddd.fhi.no/atc_ddd_index/](https://atcddd.fhi.no/atc_ddd_index/) \n28.   [WHO ATCvet - Classification of Veterinary Medicines](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20ATCvet%20-%20Classification%20of%20Veterinary%20Medicines)LICENSE Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. [https://atcddd.fhi.no/copyright_disclaimer/](https://atcddd.fhi.no/copyright_disclaimer/) Olaparib [https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01XK01](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01XK01) ATCvet Classification [https://atcddd.fhi.no/atcvet/atcvet/](https://atcddd.fhi.no/atcvet/atcvet/) \n29.   [FDA Liver Toxicity Knowledge Base (LTKB)](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Liver%20Toxicity%20Knowledge%20Base%20(LTKB))LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) Olaparib [https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-20-dataset](https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-20-dataset) FDA Liver Toxicity Knowledge Base (LTKB) [https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb](https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb) \n30.   [FDA Medication Guides](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Medication%20Guides)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) LYNPARZA [https://dps.fda.gov/medguide](https://dps.fda.gov/medguide) \n31.   [National Drug Code (NDC) Directory](https://pubchem.ncbi.nlm.nih.gov/source/National%20Drug%20Code%20(NDC)%20Directory)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) OLAPARIB [https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) \n32.   [Human Metabolome Database (HMDB)](https://pubchem.ncbi.nlm.nih.gov/source/Human%20Metabolome%20Database%20(HMDB))LICENSE HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. [https://www.hmdb.ca/citing](https://www.hmdb.ca/citing) Olaparib [http://www.hmdb.ca/metabolites/HMDB0255929](http://www.hmdb.ca/metabolites/HMDB0255929) \n33.   [Japan Chemical Substance Dictionary (Nikkaji)](https://pubchem.ncbi.nlm.nih.gov/source/Japan%20Chemical%20Substance%20Dictionary%20(Nikkaji))[http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J2.765.098H](http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J2.765.098H) \n34.   [Japan Pharmaceuticals and Medical Devices Agency (PMDA)](https://pubchem.ncbi.nlm.nih.gov/source/Japan%20Pharmaceuticals%20and%20Medical%20Devices%20Agency%20(PMDA))Olaparib [https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html](https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html) \n35.   [KEGG](https://pubchem.ncbi.nlm.nih.gov/source/KEGG)LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license [https://www.kegg.jp/kegg/legal.html](https://www.kegg.jp/kegg/legal.html) [https://www.kegg.jp/entry/D09730](https://www.kegg.jp/entry/D09730) Therapeutic category of drugs in Japan [http://www.genome.jp/kegg-bin/get_htext?br08301.keg](http://www.genome.jp/kegg-bin/get_htext?br08301.keg) USP drug classification [http://www.genome.jp/kegg-bin/get_htext?br08302.keg](http://www.genome.jp/kegg-bin/get_htext?br08302.keg) Anatomical Therapeutic Chemical (ATC) classification [http://www.genome.jp/kegg-bin/get_htext?br08303.keg](http://www.genome.jp/kegg-bin/get_htext?br08303.keg) Target-based classification of drugs [http://www.genome.jp/kegg-bin/get_htext?br08310.keg](http://www.genome.jp/kegg-bin/get_htext?br08310.keg) Drug Groups [http://www.genome.jp/kegg-bin/get_htext?br08330.keg](http://www.genome.jp/kegg-bin/get_htext?br08330.keg) Drug Classes [http://www.genome.jp/kegg-bin/get_htext?br08332.keg](http://www.genome.jp/kegg-bin/get_htext?br08332.keg) \n36.   [Metabolomics Workbench](https://pubchem.ncbi.nlm.nih.gov/source/Metabolomics%20Workbench)Olaparib [https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=152129](https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=152129) \n37.   [Nature Chemical Biology](https://pubchem.ncbi.nlm.nih.gov/source/Nature%20Chemical%20Biology)[https://pubchem.ncbi.nlm.nih.gov/substance/319530703](https://pubchem.ncbi.nlm.nih.gov/substance/319530703) \n38.   [NCI Cancer Drugs](https://pubchem.ncbi.nlm.nih.gov/source/NCI%20Cancer%20Drugs)LICENSE [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) Lynparza (Olaparib) [https://www.cancer.gov/about-cancer/treatment/drugs/olaparib](https://www.cancer.gov/about-cancer/treatment/drugs/olaparib) \n39.   [NIPH Clinical Trials Search of Japan](https://pubchem.ncbi.nlm.nih.gov/source/NIPH%20Clinical%20Trials%20Search%20of%20Japan)[https://rctportal.niph.go.jp/en/](https://rctportal.niph.go.jp/en/) \n40.   [NLM RxNorm Terminology](https://pubchem.ncbi.nlm.nih.gov/source/NLM%20RxNorm%20Terminology)LICENSE The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license. [https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html](https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html) olaparib [https://rxnav.nlm.nih.gov/id/rxnorm/1597582](https://rxnav.nlm.nih.gov/id/rxnorm/1597582) \n41.   [NORMAN Suspect List Exchange](https://pubchem.ncbi.nlm.nih.gov/source/NORMAN%20Suspect%20List%20Exchange)LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) Olaparib  NORMAN Suspect List Exchange Classification [https://www.norman-network.com/nds/SLE/](https://www.norman-network.com/nds/SLE/) \n42.   [PharmGKB](https://pubchem.ncbi.nlm.nih.gov/source/PharmGKB)LICENSE PharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license ([https://creativecommons.org/licenses/by-sa/4.0/](https://creativecommons.org/licenses/by-sa/4.0/)).  [https://www.pharmgkb.org/page/policies](https://www.pharmgkb.org/page/policies) olaparib [https://www.pharmgkb.org/chemical/PA164920420](https://www.pharmgkb.org/chemical/PA164920420) \n43.   [Pharos](https://pubchem.ncbi.nlm.nih.gov/source/Pharos)LICENSE Data accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution. [https://pharos.nih.gov/about](https://pharos.nih.gov/about) olaparib [https://pharos.nih.gov/ligands/XMQM7BMR67PF](https://pharos.nih.gov/ligands/XMQM7BMR67PF) \n44.   [Protein Data Bank in Europe (PDBe)](https://pubchem.ncbi.nlm.nih.gov/source/Protein%20Data%20Bank%20in%20Europe%20(PDBe))[http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/09L](http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/09L) \n45.   [RCSB Protein Data Bank (RCSB PDB)](https://pubchem.ncbi.nlm.nih.gov/source/RCSB%20Protein%20Data%20Bank%20(RCSB%20PDB))LICENSE Data files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data. [https://www.rcsb.org/pages/policies](https://www.rcsb.org/pages/policies) [https://www.rcsb.org/](https://www.rcsb.org/) \n46.   [Springer Nature](https://pubchem.ncbi.nlm.nih.gov/source/Springer%20Nature)[https://pubchem.ncbi.nlm.nih.gov/substance/341143310](https://pubchem.ncbi.nlm.nih.gov/substance/341143310) \n47.   [Thieme Chemistry](https://pubchem.ncbi.nlm.nih.gov/source/Thieme%20Chemistry)LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. [https://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/) [https://pubchem.ncbi.nlm.nih.gov/substance/516858117](https://pubchem.ncbi.nlm.nih.gov/substance/516858117) \n48.   [Wikidata](https://pubchem.ncbi.nlm.nih.gov/source/Wikidata)LICENSE CCZero [https://creativecommons.org/publicdomain/zero/1.0/](https://creativecommons.org/publicdomain/zero/1.0/) olaparib [https://www.wikidata.org/wiki/Q7083106](https://www.wikidata.org/wiki/Q7083106) \n49.   [Wikipedia](https://pubchem.ncbi.nlm.nih.gov/source/Wikipedia)Olaparib [https://en.wikipedia.org/wiki/Olaparib](https://en.wikipedia.org/wiki/Olaparib) \n50.   [Wiley](https://pubchem.ncbi.nlm.nih.gov/source/Wiley)[https://pubchem.ncbi.nlm.nih.gov/substance/386244507](https://pubchem.ncbi.nlm.nih.gov/substance/386244507) \n51.   [Medical Subject Headings (MeSH)](https://pubchem.ncbi.nlm.nih.gov/source/Medical%20Subject%20Headings%20(MeSH))LICENSE Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S. [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) olaparib [https://id.nlm.nih.gov/mesh/M0537510.html](https://id.nlm.nih.gov/mesh/M0537510.html) Lynparza [https://id.nlm.nih.gov/mesh/M000600994.html](https://id.nlm.nih.gov/mesh/M000600994.html) AZD 2281 [https://id.nlm.nih.gov/mesh/M0525032.html](https://id.nlm.nih.gov/mesh/M0525032.html) MeSH Tree [https://www.nlm.nih.gov/mesh/meshhome.html](https://www.nlm.nih.gov/mesh/meshhome.html) Antineoplastic Agents [https://id.nlm.nih.gov/mesh/M0001483.html](https://id.nlm.nih.gov/mesh/M0001483.html) Poly(ADP-ribose) Polymerase Inhibitors [https://id.nlm.nih.gov/mesh/M000601132.html](https://id.nlm.nih.gov/mesh/M000601132.html) \n52.   PubChem[https://pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/) PFAS and Fluorinated Compounds in PubChem [https://gitlab.com/uniluxembourg/lcsb/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf](https://gitlab.com/uniluxembourg/lcsb/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf) \n53.   [GHS Classification (UNECE)](https://pubchem.ncbi.nlm.nih.gov/source/GHS%20Classification%20(UNECE))GHS Classification [https://unece.org/about-ghs](https://unece.org/about-ghs) \n54.   [MolGenie](https://pubchem.ncbi.nlm.nih.gov/source/MolGenie)LICENSE CC-BY 4.0 [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) MolGenie Organic Chemistry Ontology [https://github.com/MolGenie/ontology/](https://github.com/MolGenie/ontology/) \n55.   [PATENTSCOPE (WIPO)](https://pubchem.ncbi.nlm.nih.gov/source/PATENTSCOPE%20(WIPO))SID 390791144 [https://pubchem.ncbi.nlm.nih.gov/substance/390791144](https://pubchem.ncbi.nlm.nih.gov/substance/390791144) \n56.   NCBI[https://www.ncbi.nlm.nih.gov/projects/linkout](https://www.ncbi.nlm.nih.gov/projects/linkout) \n\nCite\n\nDownload\n\nCONTENTS\n\n*   Title and Summary \n*   1 Structures Expand this menu \n*   2 Names and Identifiers Expand this menu \n*   3 Chemical and Physical Properties Expand this menu \n*   4 Related Records Expand this menu \n*   5 Chemical Vendors \n*   6 Drug and Medication Information Expand this menu \n*   7 Pharmacology and Biochemistry Expand this menu \n*   8 Use and Manufacturing Expand this menu \n*   9 Safety and Hazards Expand this menu \n*   10 Toxicity Expand this menu \n*   11 Associated Disorders and Diseases \n*   12 Literature Expand this menu \n*   13 Patents Expand this menu \n*   14 Interactions and Pathways Expand this menu \n*   15 Biological Test Results Expand this menu \n*   16 Classification Expand this menu \n*   17 Information Sources \n\nConnect with NLM\n\n*   [Twitter](https://twitter.com/NLM_NIH \"SM-Twitter\")\n*   [Facebook](https://www.facebook.com/nationallibraryofmedicine \"SM-Facebook\")\n*   [YouTube](https://www.youtube.com/user/NLMNIH \"SM-Youtube\")\n\n[National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\n\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)\n\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)\n\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n[Help](https://support.nlm.nih.gov/)\n\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)\n\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\n\n*   [NLM](https://www.nlm.nih.gov/)\n*   [NIH](https://www.nih.gov/)\n*   [HHS](https://www.hhs.gov/)\n*   [USA.gov](https://www.usa.gov/)"
      },
      {
        "title": "LYNPARZA® (olaparib) tablets, for oral use - accessdata.fda.gov",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf",
        "content": "oxide (150 mg tablet only). 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA and non-BRCA proteins involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum Reference ID: 4206580 This label [...] with Renal Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia 5.2 Pneumonitis 5.3 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Anticancer Agents 7.2 Drugs That May Increase Olaparib Plasma Concentrations 7.3 Drugs That May Decrease Olaparib Plasma Concentrations 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis,",
        "raw_content": "1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effectively. See full prescribing information for LYNPARZA. LYNPARZA® (olaparib) tablets, for oral use Initial U.S. Approval: 2014 -------------------------- RECENT MAJOR CHANGES -------------------------- Indications and Usage (1.3) 1/2018 Dosage and Administration (2.4) 1/2018 Warnings and Precautions (5) 1/2018 --------------------------- INDICATIONS AND USAGE -------------------------- Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. (1.1) • for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. (1.2, 2.3) Breast cancer • in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. (1.3, 2.4) ---------------------- DOSAGE AND ADMINISTRATION ---------------------- • To avoid substitution errors and overdose, do not substitute Lynparza tablets with Lynparza capsules on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. (2.1) • Recommended tablet dose is 300 mg taken orally twice daily with or without food. (2.2) • Continue treatment until disease progression or unacceptable toxicity. (2.2) • For adverse reactions, consider dose interruption or dose reduction. (2.5) • For moderate renal impairment (CLcr 31-50 mL/min), reduce dose to 200 mg twice daily. (2.7) --------------------- DOSAGE FORMS AND STRENGTHS -------------------- Tablets: 150 mg, 100 mg (3) ------------------------------ CONTRAINDICATIONS ----------------------------- None. (4) ----------------------- WARNINGS AND PRECAUTIONS ---------------------- • Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in <1.5% of patients exposed to Lynparza monotherapy and the majority of events had a fatal outcome. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. (5.1) • Pneumonitis: Occurred in <1% of patients exposed to Lynparza, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed. (5.2) • Embryo-Fetal Toxicity: Lynparza can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. (5.3, 8.1, 8.3) ------------------------------ ADVERSE REACTIONS ----------------------------- • Most common adverse reactions (≥20%) in clinical trials were anemia, nausea, fatigue (including asthenia), vomiting, neutropenia, leukopenia, nasopharyngitis/upper respiratory tract infection/influenza, respiratory tract infection, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation and stomatitis. (6.1) • Most common laboratory abnormalities (≥25%) were decrease in hemoglobin, increase in mean corpuscular volume, decrease in lymphocytes, decrease in leukocytes, decrease in absolute neutrophil count, increase in serum creatinine and decrease in platelets. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ------------------------------ DRUG INTERACTIONS ----------------------------- • CYP3A Inhibitors: Avoid concomitant use of strong or moderate CYP3A inhibitors. If the inhibitor cannot be avoided, reduce the olaparib dose. (2.6, 7.2, 12.3) • CYP3A Inducers: Avoid concomitant use of strong or moderate CYP3A inducers as decreased efficacy can occur. (7.3, 12.3) ----------------------- USE IN SPECIFIC POPULATIONS ---------------------- Lactation: Advise women not to breastfeed. (8.2) See 17 for PATIENT COUNSELING INFORMATION and MEDICATION GUIDE Revised: 1/2018 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer 1.2 Advanced gBRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy 1.3 Germline BRCA-mutated HER2-negative Metastatic Breast Cancer 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions 2.2 Recommended Dosing 2.3 Patient Selection for gBRCAm Advanced Ovarian Cancer 2.4 Patient Selection for gBRCAm HER2-negative Metastatic Breast Cancer 2.5 Dose Adjustments for Adverse Reactions 2.6 Dose Modifications for Use with CYP3A Inhibitors 2.7 Dose Modifications for Patients with Renal Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia 5.2 Pneumonitis 5.3 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Anticancer Agents 7.2 Drugs That May Increase Olaparib Plasma Concentrations 7.3 Drugs That May Decrease Olaparib Plasma Concentrations 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Maintenance Treatment of Recurrent Ovarian Cancer 14.2 Advanced gBRCA-mutated Ovarian Cancer Treated with 3 or More Prior Lines of Chemotherapy 14.3 Treatment of gBRCAm HER2-negative Metastatic Breast Cancer Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 2 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied 16.2 Storage 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. 1.2 Advanced gBRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. [see Dosage and Administration (2.3)]. 1.3 Germline BRCA-mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.4)]. 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions Lynparza is also available as a 50 mg capsule. DO NOT substitute Lynparza tablets (100 mg and 150 mg) with Lynparza capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation [see Clinical Pharmacology (12.3)]. Refer to the full prescribing information for Lynparza capsules for specific capsule dosing. 2.2 Recommended Dosing The recommended dose of Lynparza is 300 mg (two 150 mg tablets) taken orally twice daily, with or without food, for a total daily dose of 600 mg. The 100 mg tablet is available for dose reduction. Continue treatment until disease progression or unacceptable toxicity. If a patient misses a dose of Lynparza, instruct patient to take their next dose at its scheduled time. Swallow tablets whole. Do not chew, crush, dissolve, or divide tablet [see How Supplied/Storage and Handling (16.2)]. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 4 2.3 Patient Selection for gBRCAm Advanced Ovarian Cancer Select patients for the treatment of advanced ovarian cancer with Lynparza based on the presence of deleterious or suspected deleterious BRCA-mutations [see Indications and Usage (1.2) and Clinical Studies (14.2)]. Information on FDA-approved tests for the detection of BRCA-mutations is available at http://www.fda.gov/companiondiagnostics. 2.4 Patient Selection for gBRCAm HER2-negative Metastatic Breast Cancer Select patients for the treatment of HER2-negative metastatic breast cancer with Lynparza based on the presence of deleterious or suspected deleterious gBRCA-mutation [see Indications and Usage (1.3) and Clinical Studies (14.3)]. Information on FDA-approved tests for the detection of BRCA-mutations is available at http://www.fda.gov/companiondiagnostics. 2.5 Dose Adjustments for Adverse Reactions To manage adverse reactions, consider interruption of treatment or dose reduction. The recommended dose reduction is 250 mg (one 150 mg tablet and one 100 mg tablet) taken twice daily, for a total daily dose of 500 mg. If a further dose reduction is required, then reduce to 200 mg (two 100 mg tablets) taken twice daily, for a total daily dose of 400 mg. 2.6 Dose Modifications for Use with CYP3A Inhibitors Avoid concomitant use of strong or moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition. If a strong CYP3A inhibitor must be co-administered, reduce the Lynparza dose to 100 mg (one 100 mg tablet) taken twice daily (equivalent to a total daily dose of 200 mg). If a moderate CYP3A inhibitor must be co-administered, reduce the Lynparza dose to 150 mg (one 150 mg tablet) taken twice daily (equivalent to a total daily dose of 300 mg) [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. 2.7 Dose Modifications for Patients with Renal Impairment Patients with mild renal impairment (CLcr 51-80 mL/min as estimated by Cockcroft-Gault equation) do not require an adjustment in Lynparza dosing. In patients with moderate renal impairment (CLcr 31-50 ml/min) the recommended dose reduction is to 200 mg (two 100 mg tablets) twice daily, for a total daily dose of 400 mg. The pharmacokinetics of Lynparza have not been evaluated in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. 3 DOSAGE FORMS AND STRENGTHS Tablets: • 150 mg: green to green/grey, oval, bi-convex, film-coated, with debossment ‘OP150’ on one side and plain on the reverse side. • 100 mg: yellow to dark yellow, oval, bi-convex, film-coated, with debossment ‘OP100’ on one side and plain on the reverse side. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 5 4 CONTRAINDICATIONS None. 5 WARNINGS AND PRECAUTIONS 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia Overall, the incidence of Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) in patients treated with Lynparza monotherapy in clinical trials, including long-term follow up, was <1.5% (21/1680) and the majority of events had a fatal outcome. Of these, 19/21 patients had a documented BRCA mutation, 1 patient had gBRCA wildtype and in 1 patient the BRCA mutation status was unknown. Additional cases of MDS/AML have been documented in patients treated with Lynparza in combination studies. The duration of therapy with Lynparza in patients who developed secondary MDS/cancer-therapy related AML varied from < 6 months to > 2 years. All of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. Some of these patients also had a history of more than one primary malignancy or of bone marrow dysplasia. Do not start Lynparza until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt Lynparza and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Lynparza. 5.2 Pneumonitis Pneumonitis, including fatal cases, occurred in <1% of patients treated with Lynparza. If patients present with new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality occurs, interrupt Lynparza treatment and promptly assess the source of the symptoms. If pneumonitis is confirmed, discontinue Lynparza treatment and treat the patient appropriately. 5.3 Embryo-Fetal Toxicity Lynparza can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. In an animal reproduction study, administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily. Apprise pregnant women of the potential hazard to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Lynparza [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)]. Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of Lynparza [see Use in Specific Populations (8.1, 8.3)]. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 6 6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: • Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1)] • Pneumonitis [see Warnings and Precautions (5.2)] 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions presented below were reported from clinical trials in 782 patients with ovarian cancer (555 received Lynparza, 227 received placebo). Maintenance Treatment of Recurrent Ovarian Cancer SOLO-2 The safety of Lynparza for the maintenance treatment of patients with platinum sensitive gBRCAm ovarian cancer was investigated in SOLO-2. This study was a placebo-controlled, double-blind study in which 294 patients received either Lynparza 300 mg (2 x 150 mg tablets) twice daily (n=195) or placebo tablets twice daily (n=99) until disease progression or unacceptable toxicity. The median duration of study treatment was 19.4 months for patients who received Lynparza and 5.6 months for patients who received placebo. Dose interruptions due to an adverse reaction of any grade occurred in 45% of patients receiving Lynparza and 18% of those receiving placebo; dose reductions due to an adverse reaction occurred in 27% of Lynparza patients and 3% of placebo patients. The most frequent adverse reactions leading to dose interruption or reduction of Lynparza were anemia (22%), neutropenia (9%), and fatigue/asthenia (8%). Discontinuation occurred in 11% of Lynparza patients and 2% in placebo patients. Table 1 summarizes the adverse reactions that occurred in at least 20% of patients who received Lynparza in SOLO-2. Table 2 presents the laboratory abnormalities that occurred in at least 25% of patients who received Lynparza in SOLO-2. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 7 Table 1 Adverse Reactionsa in SOLO-2 (≥20% of Patients who Received Lynparza) Adverse Reactions Lynparza tablets n=195 Placebo n=99 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Blood and lymphatic disorders Anemiab 44 20 9 2 Gastrointestinal disorders Nausea 76 3 33 0 Vomiting 37 3 19 1 Diarrhea 33 2 22 0 Stomatitisc 20 1 16 0 Infections and Infestations Nasopharyngitis/ URI/ sinusitis/ rhinitis/ influenza 36 0 29 0 General disorders and administration site conditions Fatigue including asthenia 66 4 39 2 Metabolism and nutrition disorders Decreased appetite 22 0 11 0 Musculoskeletal and connective tissue disorder Arthralgia/myalgia 30 0 28 0 Nervous system disorders Dysgeusia 27 0 7 0 Headache 26 1 14 0 a. Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. b. Represents grouped term consisting of anemia, hematocrit decreased, hemoglobin decreased, iron deficiency, mean cell volume increased and red blood cell count decreased. c. Represents grouped term consisting of abscess oral, aphthous ulcer, gingival abscess, gingival disorder, gingival pain, gingivitis, mouth ulceration, mucosal infection, mucosal inflammation, oral candidiasis, oral discomfort, oral herpes, oral infection, oral mucosal erythema, oral pain, oropharyngeal discomfort, and oropharyngeal pain. In addition, the adverse reactions observed in SOLO-2 that occurred in <20% of patients receiving Lynparza were neutropenia, rash, cough, dyspepsia, leukopenia, hypomagnesemia, dizziness, thrombocytopenia, increase in creatinine, lymphopenia and edema. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 8 Table 2 Laboratory Abnormalities Reported in ≥25% of Patients in SOLO-2 Laboratory Parametera Lynparza tablets nb=195 Placebo nb=99 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Increase in mean corpuscular volume 89 - 52 - Decrease in hemoglobin 83 17 69 0 Decrease in leukocytes 69 5 48 1 Decrease in lymphocytes 67 11 37 1 Decrease in absolute neutrophil count 51 7 34 3 Increase in serum creatinine 44 0 29 0 Decrease in platelets 42 2 22 1 a. Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. b. This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. c. Represents the proportion of subjects whose mean corpuscular volume was > upper limit of normal (ULN). Study 19 The safety of Lynparza capsules as maintenance monotherapy was also evaluated in patients with platinum sensitive ovarian cancer who had received 2 or more previous platinum containing regimens in Study 19, a randomized, placebo-controlled, double-blind, multi-center study in which 264 patients received Lynparza 400 mg twice daily (n=136) or placebo (n=128). At the time of final analysis, the median duration of exposure was 8.7 months in patients who received Lynparza and 4.6 months in patients who received placebo. Adverse reactions led to dose interruptions in 35% of those receiving Lynparza and 10% of those receiving placebo; dose reductions in 26% of Lynparza and 4% of placebo; and discontinuation in 6% of Lynparza and 2% in placebo. Table 3 summarizes the adverse reactions that occurred in at least 20% of patients who received Lynparza in Study 19. Table 4 presents the laboratory abnormalities that occurred in at least 25% of patients from Study 19. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 9 Table 3 Adverse Reactionsa in Study 19 (≥20% of Patients who Received Lynparza) Adverse Reactions Lynparza capsules n=136 Placebo n=128 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Blood and lymphatic disorders Anemiab 23 7 7 1 Gastrointestinal disorders Nausea 71 2 36 0 Vomiting 35 2 14 1 Diarrhea 28 2 25 2 Constipation 22 1 12 0 General disorders and administration site conditions Fatigue (including asthenia) 63 9 46 3 Infections and infestations Respiratory tract infection 22 2 11 0 Metabolism and nutrition disorders Decreased appetite 21 0 13 0 Nervous system disorders Headache 21 0 13 1 a. Graded according to NCI CTCAE 4.0. b. Represents grouped terms of related terms that reflect the medical concept of the adverse reaction. In addition, the adverse reactions in Study 19 that occurred in <20% of patients receiving Lynparza were dyspepsia, stomatitis, dysgeusia, dizziness, increase in creatinine, neutropenia, thrombocytopenia, leukopenia, lymphopenia, dyspnea, pyrexia and edema. Table 4 Laboratory Abnormalities Reported in ≥25% of Patients in Study 19 Laboratory Parametera Lynparza capsules nb=136 Placebo nb=129 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Decrease in hemoglobin 82 8 58 1 Increase in mean corpuscular volume 82 - 51 - Decrease in leukocytes 58 4 37 2 Decrease in lymphocytes 52 10 32 3 Decrease in absolute neutrophil count 47 7 40 2 Increase in serum creatinine 45 0 14 0 Decrease in platelets 36 4 18 0 a. Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. b. This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 10 c. Represents the proportion of subjects whose mean corpuscular volume was > ULN. Treatment of Advanced gBRCAm Ovarian Cancer After 3 or More Lines of Chemotherapy Pooled data Treatment with Lynparza (capsule formulation) as monotherapy was studied in 223 patients (pooled from 6 studies) with gBRCAm advanced ovarian cancer who had received 3 or more prior lines of chemotherapy. Adverse reactions led to dose interruption in 40% of patients, dose reduction in 4% of patients, and discontinuation in 7% of patients. There were 8 (4%) patients with adverse reactions leading to death, two were attributed to acute leukemia, and one each was attributed to COPD, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, and suture rupture. The median exposure to Lynparza capsules in these patients was 5.2 months. Table 5 presents adverse reactions reported in ≥20% of patients and Table 6 presents laboratory abnormalities that occurred in at least 25% of patients from the pooled studies. Table 5 Adverse Reactions Reported in Pooled Data (≥20% of Patients who Received Lynparza) Adverse Reactions 3 or more lines of prior Chemotherapy Grades 1-4 n=223 (%) Grades 3-4 n=223 (%) Blood and Lymphatic disorders Anemia 34 18 Gastrointestinal disorders Decreased appetite 22 1 Nausea 64 3 Vomiting 43 4 Diarrhea 31 1 Dyspepsia 25 0 General disorders Fatigue/asthenia 66 8 Infections and infestations Nasopharyngitis/URI 26 0 Musculoskeletal and Connective Tissue disorders Arthralgia/musculoskeletal pain 21 0 Myalgia 22 0 Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 11 Table 6 Laboratory Abnormalities Reported ≥25% of Patients in Pooled Data Laboratory Parametera 3 or more lines of prior Chemotherapy Grades 1-4 nb=223 (%) Grades 3-4 nb=223 (%) Decrease in hemoglobin 90 15 Decrease in absolute neutrophil count 25 7 Decrease in platelets 30 3 Decrease in lymphocytes 56 17 Mean corpuscular volume elevation 57 - Increase in creatinine 30 2 a. Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. b. This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. The following adverse reactions and laboratory abnormalities have been identified in ≥10 to <20% of the 223 patients receiving Lynparza and not included in the table: cough, constipation, dysgeusia, peripheral edema, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash. The following adverse reactions and laboratory abnormalities have been identified in ≥1 to <10% of the 223 patients receiving Lynparza and not included in the table: leukopenia, stomatitis, peripheral neuropathy, pyrexia, hypomagnesemia, and venous thrombosis (including pulmonary embolism). Treatment of gBRCAm HER2-negative Metastatic Breast Cancer OlympiAD The safety of Lynparza tablets as monotherapy was also evaluated in gBRCAm patients with HER2-negative metastatic breast cancer who had previously received up to two lines of chemotherapy for the treatment of metastatic disease in OlympiAD. This study was a randomized, open-label, multi-center study in which 296 patients received either Lynparza 300 mg twice daily (n=205) or a chemotherapy (capecitabine, eribulin, or vinorelbine) of the healthcare provider’s choice (n=91) until disease progression or unacceptable toxicity. The median duration of study treatment was 8.2 months in patients who received Lynparza and 3.4 months in patients who received chemotherapy. Dose interruptions due to an adverse reaction of any grade occurred in 35% of patients receiving Lynparza and 28% of those receiving chemotherapy; dose reductions due to an adverse reaction occurred in 25% of Lynparza patients and 31% of chemotherapy patients. Discontinuation occurred in 5% of Lynparza patients and 8% in chemotherapy patients. Table 7 summarizes the adverse reactions that occurred in at least 20% of patients who received Lynparza in OlympiAD. Table 8 presents the laboratory abnormalities that occurred in at least 25% of patients who received Lynparza in OlympiAD. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 12 Table 7 Adverse Reactionsa in OlympiAD (≥20% of Patients who received Lynparza) Adverse Reactions Lynparza tablets n=205 Chemotherapy n=91 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Blood and lymphatic disorders Anemiab 40 16 26 4 Leukopeniac 25 5 31 13 Neutropeniad 27 9 50 26 Gastrointestinal disorders Nausea 58 0 35 1 Vomiting 30 0 15 1 Diarrhea 21 1 22 0 Infections and infestations Respiratory tract infectione 27 1 22 0 General disorders and administration site conditions Fatigue (including asthenia) 37 4 36 1 Nervous system disorders Headache 20 1 15 2 a. Graded according to NCI CTCAE 4.0. b. Represents grouped terms consisting of anemia (anemia erythropenia, hematocrit decreased, hemoglobin decreased and red blood cell count decreased). c. Represents grouped terms consisting of leukopenia (leukopenia and white blood cell count decreased). d. Represents grouped terms consisting of neutropenia (febrile neutropenia, granulocyte count decreased, granulocytopenia, neutropenia, neutropenic infection, neutropenic sepsis, neutrophil count decreased). e. Represents grouped terms consisting of bronchitis, influenza, lower respiratory tract infection, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, upper respiratory tract infection, upper respiratory tract infection bacterial. In addition, adverse reactions in OlympiAD that occurred in <20% of patients receiving Lynparza were cough, decreased appetite, thrombocytopenia, dysgeusia, lymphopenia, dizziness, dyspepsia, stomatitis, upper abdominal pain, rash, increase in serum creatinine and dermatitis. Table 8 Laboratory Abnormalities Reported ≥25% of Patients in OlympiAD Laboratory Parametera Lynparza tablets nb= 205 Chemotherapy nb= 91 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Increase in mean corpuscular volumec 71 - 33 - Decrease in hemoglobin 82 17 66 3 Decrease in leukocytes 71 8 70 23 Decrease in lymphocytes 73 21 63 3 Decrease in absolute neutrophil count 46 11 65 38 Decrease in platelets 33 3 28 0 a. Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 13 b. This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. c. Represents the proportion of subjects whose mean corpuscular volume was > ULN. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Lynparza capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: Hypersensitivity (rash/dermatitis). 7 DRUG INTERACTIONS 7.1 Anticancer Agents Clinical studies of Lynparza in combination with other myelosuppressive anticancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. 7.2 Drugs That May Increase Olaparib Plasma Concentrations Olaparib is primarily metabolized by CYP3A. In patients (n=57), co-administration of itraconazole, a strong CYP3A inhibitor, increased AUC of olaparib by 170%. A moderate CYP3A inhibitor, fluconazole, is predicted to increase the AUC of olaparib by 121%. Avoid concomitant use of strong CYP3A inhibitors such as itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir or moderate CYPA inhibitors such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. If the strong or moderate CYP3A inhibitors must be co-administered, reduce the dose of Lynparza [see Dosage and Administration (2.5)]. Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during Lynparza treatment since they are CYP3A inhibitors [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. 7.3 Drugs That May Decrease Olaparib Plasma Concentrations In patients (n=22), co-administration of rifampicin, a strong CYP3A inducer, decreased AUC of olaparib by 87%. A moderate CYP3A inducer, efavirenz, is predicted to decrease the AUC of olaparib by approximately 60%. Avoid concomitant use of strong CYP3A inducers such as phenytoin, rifampicin, carbamazepine, and St. John’s Wort or moderate CYP3A4 inducers such as bosentan, efavirenz, etravirine, modafinil, and nafcillin. If a moderate CYP3A inducer cannot be avoided, there is a potential for decreased efficacy of Lynparza [see Clinical Pharmacology (12.3)]. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 14 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily [see Data]. Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies. Data Animal Data In a fertility and early embryonic development study in female rats, olaparib was administered orally for 14 days before mating through to day 6 of pregnancy, which resulted in increased post-implantation loss at a dose level of 15 mg/kg/day (with maternal systemic exposures approximately 7% of the human exposure (AUC0-24h) at the recommended dose). In an embryo-fetal development study, pregnant rats received oral doses of 0.05 and 0.5 mg/kg/day olaparib during the period of organogenesis. A dose of 0.5 mg/kg/day (with maternal systemic exposures approximately 0.18% of human exposure (AUC0-24h) at the recommended dose) caused embryo-fetal toxicities including increased post-implantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital) and diaphragm (hernia). Additional abnormalities or variants included incomplete or absent ossification (vertebrae/sternebrae, ribs, limbs) and other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter and umbilical artery. Some findings noted above in the eyes, ribs and ureter were observed at a dose of 0.05 mg/kg/day olaparib at lower incidence. 8.2 Lactation Risk Summary No data are available regarding the presence of olaparib in human milk, or on its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infants from Lynparza, advise a lactating woman not to breastfeed during treatment with Lynparza and for one month after receiving the last dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 15 Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with Lynparza. Contraception Females Lynparza can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for at least 6 months following the last dose. Males Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of Lynparza. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of Lynparza [see Use in Specific Populations (8.1)and Nonclinical Toxicology (13.1)]. 8.4 Pediatric Use The safety and efficacy of Lynparza have not been established in pediatric patients. 8.5 Geriatric Use In clinical studies of Lynparza enrolling 687 patients with advanced solid tumors who received Lynparza tablets 300 mg twice daily as monotherapy, 146 (21%) patients were aged ≥65 years, and this included 29 (4%) patients who were aged ≥75 years. No patients were aged ≥85 years. No overall differences in the safety or effectiveness of Lynparza were observed between younger and older patients. 8.6 Hepatic Impairment No adjustment to the starting dose is required in patients with mild hepatic impairment. A 15% increase in mean exposure (AUC) was observed in patients with mild hepatic impairment (based on Child-Pugh classification A) compared to patients with normal hepatic function. There are no data in patients with moderate or severe hepatic impairment [see Clinical Pharmacology (12.3)]. 8.7 Renal Impairment No adjustment to the starting dose is required in patients with mild renal impairment, but patients should be monitored closely for toxicity. A 24% increase in mean exposure (AUC) was observed in patients with mild renal impairment (CLcr = 51-80 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). A 44% increase in AUC was observed in patients with moderate renal impairment (CLcr = 31-50 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). For patients with moderate renal impairment, reduce the dose of Lynparza to 200 mg twice daily [see Dosage and Administration (2.6)]. There are no data in patients with severe renal impairment or end-stage disease (CLcr ≤30 mL/min) [see Clinical Pharmacology (12.3)]. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 16 10 OVERDOSAGE There is no specific treatment in the event of Lynparza overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should follow general supportive measures and should treat the patient symptomatically. 11 DESCRIPTION Olaparib is an inhibitor of the mammalian polyadenosine 5’-diphosphoribose polymerase (PARP) enzyme. The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one and it has the following chemical structure: The empirical molecular formula for Lynparza is C24H23FN4O3 and the relative molecular mass is 434.46. Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility across the physiological pH range. Lynparza tablets for oral administration contain 100 mg or 150 mg of olaparib. Inactive ingredients in the tablet core are copovidone, mannitol, colloidal silicon dioxide and sodium stearyl fumarate. The tablet coating consists of hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow and ferrosoferric oxide (150 mg tablet only). 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA and non-BRCA proteins involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 17 response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed. 12.3 Pharmacokinetics Lynparza is available as a tablet and capsule formulation. The oral bioavailability of the tablet formulation is higher than the capsule formulation. Population pharmacokinetic analyses have shown that the steady state exposure (AUC) following 300 mg tablet twice daily was 77% higher compared to that following 400 mg capsule twice daily. The olaparib geometric mean AUC and Cmax following a single 300 mg tablet dose were 42.0 μg*h/mL (n = 204) and 5.8 μg/mL (n = 204), respectively, and the steady state geometric mean AUC and Cmax following 300 mg tablet twice daily were 49.0 μg*h/mL (n = 227) and 7.7 μg/mL (n = 227), respectively. Olaparib showed time-dependent PK that the steady state clearance decreased by 15% after multiple dosing. Absorption Following oral administration of olaparib, absorption is rapid with median peak plasma concentrations typically achieved 1.5 hours after dosing. An AUC mean accumulation ratio of 1.8 is observed at steady state following multiple dosing of 300 mg tablets twice daily. Systemic exposure (single dose AUC) to olaparib increases approximately proportionally with doses over the dose range of 25 mg to 450 mg, Cmax increased slightly less than proportionally for the same dose range. Co-administration of a high fat meal with olaparib slowed the rate (tmax delayed by 2.5 hours) of absorption, but did not significantly alter the extent of olaparib absorption (mean AUC increased by approximately 8%). Distribution Olaparib had a mean (± standard deviation) apparent volume of distribution of 158 ± 136 L after a single 300 mg dose of olaparib. The in vitro protein binding of olaparib is approximately 82%. Metabolism In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of olaparib. Following oral dosing of 14C-olaparib to female patients, unchanged olaparib accounted for the majority of the circulating radioactivity in plasma (70%). It was extensively metabolized with unchanged drug accounting for 15% and 6% of radioactivity in urine and feces, respectively. The majority of the Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 18 metabolism is attributable to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation. Excretion A mean (± standard deviation) terminal plasma half-life of 14.9 ± 8.2 hours and apparent plasma clearance of 7.4 ± 3.9 L/h were observed after a single 300 mg dose of olaparib. Following a single dose of 14C-olaparib, 86% of the dosed radioactivity was recovered within a 7-day collection period, 44% via the urine and 42% via the feces. The majority of the material was excreted as metabolites. Drug Interactions Based on the data from a drug-interaction trial (n=57), the AUC and Cmax of olaparib increased by 170% and 42%, respectively, when olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) may increase the AUC and Cmax of olaparib by 121% and 14%, respectively. Based on the data from a drug-interaction trial (n=22), the AUC and Cmax of olaparib decreased by 87% and 71%, respectively, when olaparib was administered in combination with rifampicin, a strong CYP3A inducer. Simulations suggested that a moderate CYP3A inducer (efavirenz) may decrease the AUC and Cmax of olaparib by approximately 60% and 31%, respectively. In vitro studies have shown that olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Olaparib is predicted to be a weak CYP3A inhibitor in humans. In vitro studies also indicated that olaparib is an inhibitor of UGT1A1, BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. The clinical relevance of these findings is unknown. In vitro, olaparib is a substrate of, and inhibits, the efflux transporter P-gp. The potential for olaparib to induce P-gp has not been evaluated. Pharmacokinetics in Specific Populations Hepatic Impairment In a hepatic impairment trial, the mean AUC increased by 15% and the mean Cmax by 13% when olaparib was dosed in patients with mild hepatic impairment (Child-Pugh classification A; n=9) compared with patients with normal hepatic function (n=13). Mild hepatic impairment had no effect on the protein binding of olaparib and therefore total plasma exposure was representative of free drug. There are no data in patients with moderate or severe hepatic impairment. Renal Impairment In a renal impairment trial, the mean AUC increased by 24% and Cmax by 15%, when olaparib was dosed in patients with mild renal impairment (CLcr = 51-80 mL/min defined by the Cockcroft-Gault equation; n=13) and by 44% and 26%, respectively, when olaparib was dosed in patients with moderate renal impairment (CLcr = 31-50 mL/min; n=13), compared to those with normal renal function (CLcr ≥81 mL/min; n=12). There was no evidence of a relationship between the extent of plasma protein binding of Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 19 olaparib and creatinine clearance. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤ 30 mL/min). 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with olaparib. Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian Chinese hamster ovary (CHO) cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of olaparib and indicates potential for genotoxicity in humans. Olaparib was not mutagenic in a bacterial reverse mutation (Ames) test. In a fertility study, female rats received oral olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before mating through the first week of pregnancy. There were no adverse effects on mating and fertility rates at doses up to 15 mg/kg/day (maternal systemic exposures approximately 7% of the human exposure (AUC0-24h) at the recommended dose). In a male fertility study, olaparib had no effect on mating and fertility in rats at oral doses up to 40 mg/kg/day following at least 70 days of olaparib treatment (with systemic exposures of approximately 5% of the human exposure (AUC0-24h) at the recommended dose). 14 CLINICAL STUDIES 14.1 Maintenance Treatment of Recurrent Ovarian Cancer The efficacy of Lynparza was investigated in two randomized, placebo-controlled, double-blind, multicenter studies in patients with recurrent ovarian cancers who were in response to platinum-based therapy. SOLO-2 SOLO-2 (NCT01874353) was a double-blind, placebo-controlled trial in which patients (n=295) with gBRCAm ovarian, fallopian tube, or primary peritoneal cancer were randomized (2:1) to receive Lynparza tablets 300 mg orally twice daily or placebo until unacceptable toxicity or progressive disease. Randomization was stratified by response to last platinum chemotherapy (complete versus partial) and time to disease progression in the penultimate platinum-based chemotherapy prior to enrollment (6-12 months versus > 12 months). All patients had received at least two prior platinum-containing regimens and were in response (complete or partial) to their most recent platinum-based regimen. All patients had a deleterious or suspected deleterious germline BRCA-mutation as detected either by a local test (n= 236) or central Myriad CLIA test (n=59), subsequently confirmed by BRACAnalysis CDx (n= 286). The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Additional endpoints included overall survival (OS). Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 20 The median age of patients treated with Lynparza was 56 years (range: 28 to 83) and 56 years (range: 39 to 78) among patients treated with placebo. The Eastern Cooperative Oncology Group (ECOG) performance score was 0 in 83% of patients receiving Lynparza and 78% of patients receiving placebo. Of all patients, 89% were White, 17% were enrolled in the U.S. or Canada, 47% were in complete response to their most recent platinum-based regimen, and 40% had a progression-free interval of 6-12 months since their penultimate platinum regimen. Prior bevacizumab therapy was reported for 17% of those treated with Lynparza and 20% of those receiving placebo. Approximately 44% of patients on the Lynparza arm and 37% on placebo had received three or more lines of platinum-based treatment. SOLO-2 demonstrated a statistically significant improvement in investigator-assessed PFS in patients randomized to Lynparza as compared with placebo (Table 9 and Figure 1). Results from a blinded independent review were consistent. At the time of the analysis of PFS, overall survival (OS) data were not mature with 24% of events. Table 9 Efficacy Results – SOLO-2 (Investigator Assessment) Lynparza tablets (n=196) Placebo (n=99) Progression-Free Survival Number of events (%) 107 (54.6%) 80 (80.8%) Median, months 19.1 5.5 Hazard ratioa (95% CI) 0.30 (0.22, 0.41) p-valueb <0.0001 a. Hazard ratio from the stratified proportional hazards model, stratified by response to last platinum chemotherapy (complete versus partial) and time to disease progression in the penultimate platinum-based chemotherapy prior to enrollment. b. The p-value is derived from a stratified log-rank test. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 21 Figure 1: Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival – SOLO-2 Study 19 Study 19 (NCT00753545) was a double-blind, placebo-controlled trial in which patients (n=265) with platinum-sensitive ovarian cancer who had received 2 or more previous platinum-containing regimens were randomized (1:1) to receive Lynparza capsules 400 mg orally twice daily or placebo until unacceptable toxicity or progressive disease. Randomization was stratified by response to last platinum chemotherapy (CR versus PR), time to disease progression in the penultimate platinum-based chemotherapy (6-12 months versus > 12 months), and descent (Jewish versus non-Jewish). The major efficacy outcome measure of the study was investigator-assessed PFS evaluated according to RECIST, version 1.0. The median age of patients treated with Lynparza (n=136) was 58 years (range: 21 to 89) and 59 years (range 33 to 84) among patients treated with placebo (n=129). ECOG performance status was 0 in 81% of patients receiving Lynparza and 74% of patients receiving placebo. Of all patients, 97% were White, 19% were enrolled in the US or Canada, 45% were in complete response following their most recent platinum chemotherapy regimen, and 40% had a progression-free interval of 6-12 months since their penultimate platinum. Prior bevacizumab therapy was reported for 13% of patients receiving Lynparza and 16% of patients receiving placebo. A retrospective analysis for germline BRCA mutation status, Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 22 some performed using the Myriad test, indicated that 36% (n=96) of patients from the ITT population had deleterious gBRCA mutation, including 39% (n=53) of patients on Lynparza and 33% (n=43) of patients on placebo. Study 19 demonstrated a statistically significant improvement in investigator-assessed PFS in patients treated with Lynparza versus placebo (Table 10 and Figure 2). Table 10 Efficacy Results - Study 19 (Investigator Assessment) Lynparza capsules (n=136) Placebo (n=129) Progression-Free Survival Number of events (%) 60 (44%) 94 (73%) Median, months 8.4 4.8 Hazard ratioa (95% CI) 0.35 (0.25, 0.49) p-valueb <0.0001 Overall Survivalc Number of events (%) 98 (72%) 112 (87%) Median, months 29.8 27.8 Hazard ratio (95% CI) 0.73 (0.55, 0.95) a. Hazard ratio is derived from a stratified proportional hazards model, stratified by response to last platinum chemotherapy, time to disease progression in the penultimate platinum-based chemotherapy and Jewish and non-Jewish descent. b. The p-value is derived from a stratified log-rank test. c. Without adjusting for multiple analyses. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 23 14.2 Advanced gBRCA-mutated Ovarian Cancer Treated with 3 or More Prior Lines of Chemotherapy The efficacy of Lynparza was also investigated in a single-arm study of patients with deleterious or suspected deleterious gBRCAm advanced cancers. A total of 137 patients with measurable, advanced gBRCAm ovarian cancer treated with three or more prior lines of chemotherapy were enrolled. All patients received Lynparza capsules at a dose of 400 mg twice daily as monotherapy until disease progression or intolerable toxicity. Objective response rate (ORR) and duration of response (DOR) were assessed by the investigator according to RECIST, version 1.0. The median age of the patients was 58 years, the majority were White (94%) and 93% had an ECOG PS of 0 or 1. Deleterious or suspected deleterious gBRCAm status was verified retrospectively in 97% (59/61) of the patients for whom blood samples were available by the BRACAnalysis CDxTM. Efficacy results are summarized in Table 11. Figure 2: Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival – Study 19 Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 24 Table 11 Overall Response and Duration of Response in Patients with gBRCA-mutated Advanced Ovarian Cancer Who Received 3 or More Lines of Chemotherapy n=137 Objective Response Rate (95% CI) 34% (26, 42) Complete Response 2% Partial Response 32% Median DOR in months (95% CI) 7.9% (5.6, 9.6) 14.3 Treatment of gBRCAm HER2-negative Metastatic Breast Cancer OlympiAD OlympiAD (NCT02000622) was an open-label study in which patients (n=302) with gBRCAm HER2-negative metastatic breast cancer were randomized 2:1 to receive Lynparza 300 mg tablets or healthcare provider’s choice of chemotherapy (capecitabine, eribulin, or vinorelbine, at standard doses) until progression or unacceptable toxicity. Randomization was stratified by prior use of chemotherapy for metastatic disease (yes vs no), hormone receptor status (hormone receptor positive vs triple negative), and previous use of platinum-based chemotherapy (yes vs no). Patients were required to have received treatment with an anthracycline (unless contraindicated) and a taxane, in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor-positive disease must have progressed on at least 1 endocrine therapy (adjuvant or metastatic), or have disease that the treating healthcare provider believed to be inappropriate for endocrine therapy. Patients with prior platinum therapy were required to have no evidence of disease progress during platinum treatment. No prior treatment with a PARP inhibitor was permitted. Of the 302 patients randomized onto OlympiAD, 299 were tested with the BRACAnalysis CDX and 297 were confirmed to have deleterious or suspected deleterious gBRCAm status; 202 were randomized to the Lynparza arm and 95 to the healthcare provider’s choice of chemotherapy arm. Among the 205 patients treated with Lynparza, the median age was 44 years (range: 22 to 76), 65% were White, 4% were males and all the patients had an ECOG PS of 0 or 1. Approximately 50% of patients had triple-negative tumors and 50% had estrogen receptor and/or progesterone receptor positive tumors and the proportions were balanced across treatment arms. Patients in each treatment arm had received a median of 1 prior chemotherapy regimen for metastatic disease; approximately 30% had not received a prior chemotherapy regimen for metastatic breast cancer. Twenty-one percent of patients in the Lynparza arm and 14% in the chemotherapy arm had received platinum therapy for metastatic disease. Seven percent of patients in each treatment arm had received platinum therapy for localized disease. The major efficacy outcome measure was PFS assessed by blinded independent central review (BICR) using RECIST version 1.1. A statistically significant improvement in PFS was demonstrated for the Lynparza arm compared to the chemotherapy arm. Efficacy data for OlympiAD are displayed in Table 12 and Figure 3. Consistent results were observed across patient subgroups defined by study stratification factors. An exploratory analysis of investigator-assessed PFS was consistent with the BICR-assessed PFS results. The overall survival (OS) data were not mature at the time of the final PFS analysis (46% of patients had died). Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 25 Table 12 Efficacy Results - OlympiAD (BICR-assessed) Lynparza tablets (n=205) Chemotherapy (n=97) Progression-Free Survival Number of events (%) 163 (80%) 71 (73%) Median, months 7.0 4.2 Hazard ratio (95% CI)a 0.58 (0.43, 0.80) p-value b 0.0009 Patients with Measurable Disease n=167 n=66 Objective Response Rate (95% CI) c 52% (44, 60) 23% (13, 35) a. Hazard ratio is derived from a stratified log-rank test, stratified by ER, PgR negative versus ER and or PgR positive and prior chemotherapy (yes versus no) b. For PFS, p-value (2-sided) was compared to 0.05 c. Response based on confirmed responses. The confirmed complete response rate was 7.8% for Lynparza compared to 1.5% for chemotherapy arm. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 26 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Lynparza is available as 150 mg and 100 mg tablets. • 150 mg tablets: green to green/grey, oval, bi-convex, film-coated tablet, with debossment ‘OP150’ on one side and plain on the reverse, are available in: o Bottles of 60 tablets (NDC 0310-0679-60) and o Bottles of 120 tablets (NDC 0310-0679-12). • 100 mg tablets: yellow to dark yellow, oval, bi-convex, film-coated tablet, with debossment ‘OP100’on one side and plain on the reverse, are available in: o Bottles of 60 tablets (NDC 0310-0668-60) and o Bottles of 120 tablets (NDC 0310-0668-12). Figure 3: Kaplan-Meier Curves of Progression-Free Survival – OlympiAD Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 27 16.2 Storage Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Store in original bottle to protect from moisture. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). • Administration Instructions: Inform patients that Lynparza should be taken twice daily with or without food. Instruct patients that if they miss a dose of Lynparza, they should take their next normal dose at the usual time. Swallow each tablet whole. Do not chew, crush, dissolve, or divide tablet. Do not take more than 4 tablets daily [see Dosage and Administration (2.2)]. Inform patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice while taking Lynparza [see Drug Interactions (7.3)]. • Inform patients not to substitute Lynparza tablets (100 mg and 150 mg) with Lynparza capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation [see Dosage and Administration (2.1)]. • MDS/AML: Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. This may be a sign of hematological toxicity or a more serious uncommon bone marrow problem called ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukemia’ (AML) which have been reported in patients treated with Lynparza [see Warnings and Precautions (5.1)]. • Pneumonitis: Advise patients to contact their healthcare provider if they experience any new or worsening respiratory symptoms including shortness of breath, fever, cough, or wheezing [see Warnings and Precautions (5.2)]. • Embryo-Fetal Toxicity: Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for 6 months after the last dose. Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months after receiving the last dose of Lynparza. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of Lynparza [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1, 8.3)]. • Lactation: Advise patients not to breastfeed while taking Lynparza and for one month after receiving the last dose [see Use in Specific Populations (8.2)]. • Nausea/Vomiting: Advise patients that mild or moderate nausea and/or vomiting is very common in patients receiving Lynparza and that they should contact their healthcare provider who will advise on available antiemetic treatment options. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 28 Medication Guide Lynparza (Lin-par-zah) (olaparib) tablets What is the most important information I should know about Lynparza? Lynparza may cause serious side effects, including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Lynparza. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Lynparza. Symptoms of low blood cell counts are common during treatment with Lynparza, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include: • weakness • weight loss • fever • frequent infections • blood in urine or stool • shortness of breath • feeling very tired • bruising or bleeding more easily Your healthcare provider will do blood tests to check your blood cell counts: • before treatment with Lynparza • every month during treatment with Lynparza • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Lynparza until your blood cell counts improve. Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death. What is Lynparza? Lynparza is a prescription medicine used to treat adults with: • Ovarian cancer ∘ who have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. Lynparza is used after the cancer has responded to treatment with platinum-based chemotherapy or ∘ who have advanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that Lynparza is right for you. • Breast cancer ∘ who have a certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that Lynparza is right for you. It is not known if Lynparza is safe and effective in children. Before taking Lynparza, tell your healthcare provider about all of your medical conditions, including if you: • have lung or breathing problems Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 29 • have kidney problems • are pregnant, become pregnant, or plan to become pregnant. Lynparza can harm your unborn baby and may cause loss of pregnancy (miscarriage). o If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Lynparza. o Females who are able to become pregnant should use effective birth control (contraception) during treatment with Lynparza and for 6 months after the last dose of Lynparza. Talk to your healthcare provider about birth control methods that may be right for you. o Males with female partners who are pregnant or able to become pregnant should use effective birth control (contraception) during treatment with Lynparza and for 3 months after the last dose of Lynparza. o Do not donate sperm during treatment with Lynparza and for 3 months after your final dose. • are breastfeeding or plan to breastfeed. It is not known if Lynparza passes into your breast milk. Do not breastfeed during treatment with Lynparza and for 1 month after receiving the last dose of Lynparza. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider right away if you become pregnant. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Lynparza and certain other medicines may affect how Lynparza works and may cause side effects. How should I take Lynparza? • Take Lynparza tablets exactly as your healthcare provider tells you. • Your healthcare provider may temporarily stop treatment with Lynparza or change your dose of Lynparza if you experience side effects. • Lynparza comes as tablets and capsules. Lynparza tablets and capsules are not the same. If your healthcare provider prescribes Lynparza tablets for you, do not take Lynparza capsules. Do not take more than 4 Lynparza tablets in 1 day. If you have any questions about Lynparza, please talk to your healthcare provider or pharmacist. • Take Lynparza by mouth 2 times a day. • Each dose should be taken about 12 hours apart. • Swallow Lynparza tablets whole. Do not chew, crush, dissolve, or divide the tablets. • Take Lynparza with or without food. • If you miss a dose of Lynparza, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose. • If you take too much Lynparza, call your healthcare provider or go to the nearest hospital emergency room right away. What should I avoid while taking Lynparza? • Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with Lynparza since they may increase the level of Lynparza in your blood. What are the possible side effects of Lynparza? Lynparza may cause serious side effects. See “What is the most important information I should know about Lynparza?” The most common side effects of Lynparza are: • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms. Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda 30 • low number of red or white blood cells • tiredness or weakness • sore throat or runny nose • diarrhea • joint, muscle, and back pain • headache • constipation • changes in the way food tastes • loss of appetite • mouth sores • respiratory tract infections • changes in kidney function blood test • low number of platelets • indigestion or heartburn These are not all the possible side effects of Lynparza. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Lynparza? • Store Lynparza at room temperature, between 68°F to 77°F (20°C to 25°C). • Store Lynparza in the original bottle to protect it from moisture. Keep Lynparza and all medicines out of the reach of children. General information about the safe and effective use of Lynparza Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Lynparza for a condition for which it was not prescribed. Do not give Lynparza to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Lynparza that is written for health professionals. What are the ingredients in Lynparza? Active ingredient: olaparib Inactive ingredients: Tablet contains: copovidone, mannitol, colloidal silicon dioxide and sodium stearyl fumarate Tablet coating contains: hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow and ferrosoferric oxide (150 mg tablet only) Lynparza is a registered trademark of the AstraZeneca group of companies. ©AstraZeneca 2017 Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 For more information, call 1-800-236-9933 or go to www.Lynparza.com. This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 1/2018 Reference ID: 4206580 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda"
      },
      {
        "title": "center for drug evaluation and research - accessdata.fda.gov",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/206162Orig1s007.pdf",
        "content": "mg capsules for oral administration. Each capsule contains olaparib as the active ingredient and the following inactive ingredients:  Capsule content: lauroyl polyoxylglycerides  Capsule shell: hypromellose, titanium dioxide, gellan gum, potassium acetate  Capsule printing ink: shellac, ferrosoferric oxide 10 Reference ID: 4140741 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following [...] for Patients with Renal Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia 5.2 Pneumonitis 5.3 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Anticancer Agents 7.2 Drugs That May Increase Olaparib Plasma Concentrations 7.3 Drugs That May Decrease Olaparib Plasma Concentrations 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis,",
        "raw_content": "CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 206162Orig1s007 Trade Name: Lynparza Generic or Proper Name: olaparib Sponsor: AstraZeneca Pharmaceuticals LP Approval Date: August 17, 2017 Indication: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. CENTER FOR DRUG EVALUATION AND RESEARCH 206162Orig1s007 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters Labeling X REMS Summary Review Officer/Employee List X Office Director Memo Cross Discipline Team Leader Review Medical Review(s) X Chemistry Review(s) Environmental Assessment Pharmacology Review(s) Statistical Review(s) Microbiology / Virology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) Other Reviews X Risk Assessment and Risk Mitigation Review(s) Proprietary Name Review(s) Administrative/Correspondence Document(s) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206162Orig1s007 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 206162/S-007 SUPPLEMENT APPROVAL FULFILLMENT OF POSTMARKETING REQUIREMENT RELEASE FROM POSTMARKETING REQUIREMENT AstraZeneca Pharmaceuticals LP Attention: Karen McCullough, PhD Director, Global Regulatory Affairs Oncology One MedImmune Way Gaithersburg, MD 20878 Dear Dr. McCullough: Please refer to your Supplemental New Drug Application (sNDA) dated May 17, 2017, received May 17, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lynparza® (olaparib), oral capsules. This Prior Approval supplemental new drug application provides for updates to the Prescribing Information based on the post-marketing signal of hypersensitivity characterized by rash and dermatitis. In addition, this supplement provides, via cross-reference to NDA 208558 for Lynparza® (olaparib) tablets, the final clinical study report for PMR 2824-1 from the December 19, 2014, approval letter for this NDA. Notifications were added to the Prescribing Information regarding the differences in the dosing and bioavailability of the capsule and tablet formulations. APPROVAL & LABELING We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. Reference ID: 4140741 NDA 206162/S-007 Page 2 Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U CM072392.pdf. The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s). SUBPART H FULFILLED We approved this NDA under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of this supplement fulfills your commitment made under 21 CFR 314.510 for the following postmarketing requirement: 2824-1 Submit the progression-free survival (PFS) and overall survival (OS) analyses with datasets from clinical trial D0818C00002, SOLO-2, the ongoing randomized double-blind, placebo-controlled, multi-center trial to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum-based chemotherapy. Interim Report (PFS analysis) 02/2016 Trial Completion Date 12/2018 Final Report Submission (OS analysis) 03/2019 RELEASE FROM POSTMARKETING REQUIREMENT We have received your submission dated August 14, 2017, providing authorization to cross-reference NDA 208558 for the final clinical study report for PMR 2824-1 listed in our December 19, 2014, approval letter: 2824-2 Submit the progression-free survival (PFS) and overall survival (OS) analyses with datasets from clinical trial D0816C00010, a randomized trial establishing the superiority of olaparib over physician’s choice single-agent chemotherapy in the treatment of platinum sensitive relapsed ovarian cancer in patients carrying deleterious or suspected deleterious germline BRCA1/2 mutations. Reference ID: 4140741 NDA 206162/S-007 Page 3 The original timetable you submitted on November 13, 2014, states that you will conduct this trial according to the following schedule: Interim report: 06/2018 Trial Completion Date: 03/2020 Final Report Submission: 06/2020 We have reviewed your submission and have determined that you are released from the above postmarketing requirement for the following reasons: Interim progression-free survival data from SOLO-2 have verified the clinical benefit of olaparib and therefore olaparib capsules for monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy is granted regular approval. Therefore, PMR 2824-2 is no longer needed. We remind you that there are postmarketing requirements listed in the December 19, 2014, approval letter that are still open. REQUIRED PEDIATRIC ASSESSMENTS Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because none of these criteria apply to your application, you are exempt from this requirement. PROMOTIONAL MATERIALS You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to: OPDP Regulatory Project Manager Food and Drug Administration Center for Drug Evaluation and Research Office of Prescription Drug Promotion (OPDP) 5901-B Ammendale Road Beltsville, MD 20705-1266 Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: Reference ID: 4140741 NDA 206162/S-007 Page 4 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U CM443702.pdf ). You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm. REPORTING REQUIREMENTS We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). If you have any questions, call Rajesh Venugopal, Senior Regulatory Project Manager, at (301) 796-4730. Sincerely, {See appended electronic signature page} Julia Beaver, MD Acting Director Division of Oncology Products 1 Office of Hematology and Oncology Products Center for Drug Evaluation and Research ENCLOSURE: Content of Labeling Reference ID: 4140741 ---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.\n---------------------------------------------------------------------------------------------------------/s/ ----------------------------------------------------JULIA A BEAVER 08/17/2017 Reference ID: 4140741 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206162Orig1s007 LABELING HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effectively. See full prescribing information for LYNPARZA. LYNPARZA® (olaparib) capsules, for oral use Initial U.S. Approval: 2014 -------------------------- RECENT MAJOR CHANGES --------------------------Indications and Usage (1.1) 08/2017 Dosage and Administration (2.2) 01/2017 Dosage and Administration (2.5) 10/2016 Warnings and Precautions (5.1) 10/2016 Warnings and Precautions (5.3) 01/2017 --------------------------- INDICATIONS AND USAGE --------------------------Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. (1.1) ---------------------- DOSAGE AND ADMINISTRATION ----------------------  To avoid substitution errors and overdose, do not substitute Lynparza capsules with Lynparza tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. (2.2)  Recommended dose is 400 mg taken orally twice daily with or without food. (2.3)  Continue treatment until disease progression or unacceptable toxicity. (2.3)  For adverse reactions, consider dose interruption of treatment or dose reduction. (2.4)  For moderate renal impairment (CLcr 31-50 mL/min), reduce dose to 300 mg twice daily. (2.6) --------------------- DOSAGE FORMS AND STRENGTHS --------------------Capsules: 50 mg. (3) ------------------------------ CONTRAINDICATIONS -----------------------------None. ----------------------- WARNINGS AND PRECAUTIONS ---------------------- Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): occurred in patients exposed to Lynparza, and the majority of reports were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. (5.1)  Pneumonitis: occurred in patients exposed to Lynparza, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed. (5.2)  Embryo-Fetal Toxicity: Lynparza can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.3, 8.1, 8.3) ------------------------------ ADVERSE REACTIONS ----------------------------- Most common adverse reactions (≥20%) in clinical trials were anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngitis/URI, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash and abdominal pain/discomfort. (6.1)  Most common laboratory abnormalities (≥25%) were increase in creatinine, mean corpuscular volume elevation, decrease in hemoglobin, decrease in lymphocytes, decrease in absolute neutrophil count, and decrease in platelets. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ------------------------------ DRUG INTERACTIONS ----------------------------- CYP3A Inhibitors: Avoid concomitant use of strong and moderate CYP3A inhibitors. If the inhibitor cannot be avoided, reduce the dose. (2.3, 7.2)  CYP3A Inducers: Avoid concomitant use of strong and moderate CYP3A inducers. If a moderate CYP3A inducer cannot be avoided, be aware of a potential for decreased efficacy. (7.3) ----------------------- USE IN SPECIFIC POPULATIONS ---------------------- Lactation: Advise women not to breastfeed. (8.2) See 17 for PATIENT COUNSELING INFORMATION and MEDICATION GUIDE Revised: 8/2017 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Treatment of gBRCA-mutated Advanced Ovarian Cancer 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection 2.2 Important Administration Instructions 2.3 Recommended Dosing 2.4 Dose Adjustments for Adverse Reactions 2.5 Dose Modifications for Use with CYP3A Inhibitors 2.6 Dose Modifications for Patients with Renal Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia 5.2 Pneumonitis 5.3 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Anticancer Agents 7.2 Drugs That May Increase Olaparib Plasma Concentrations 7.3 Drugs That May Decrease Olaparib Plasma Concentrations 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied 16.2 Storage 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. 1 Reference ID: 4140741 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Treatment of gBRCA-mutated Advanced Ovarian Cancer Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection Select patients for the treatment of advanced ovarian cancer with Lynparza based on the presence of deleterious or suspected deleterious germline BRCA-mutations [see Indications and Usage (1) and Clinical Studies (14)]. Information on FDA-approved test for the detection of BRCA-mutations is available at http://www.fda.gov/companiondiagnostics. 2.2 Important Administration Instructions Lynparza is also available as 100 mg and 150 mg tablets. DO NOT substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. Refer to the full prescribing information for Lynparza tablets for specific tablet dosing. 2.3 Recommended Dosing The recommended dose of Lynparza is 400 mg (eight 50 mg capsules) taken orally twice daily with or without food, for a total daily dose of 800 mg. Continue treatment until disease progression or unacceptable toxicity. If a patient misses a dose of Lynparza, instruct patients to take their next dose at its scheduled time. Swallow capsule whole. Do not chew, dissolve, or open capsule. Do not take capsules which appear deformed or show evidence of leakage [see How Supplied/Storage and Handling (16.2)]. 2.4 Dose Adjustments for Adverse Reactions To manage adverse reactions, consider dose interruption of treatment or dose reduction. The recommended dose reduction is to 200 mg (four 50 mg capsules) taken twice daily, for a total daily dose of 400 mg. If a further final dose reduction is required, then reduce to 100 mg (two 50 mg capsules) taken twice daily, for a total daily dose of 200 mg. 2 Reference ID: 4140741 2.5 Dose Modifications for Use with CYP3A Inhibitors Avoid concomitant use of strong and moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition. If the inhibitor cannot be avoided, reduce the Lynparza dose to 150 mg (three 50 mg capsules) taken twice daily for a strong CYP3A inhibitor or 200 mg (four 50 mg capsules) taken twice daily for a moderate CYP3A inhibitor [see Drug Interactions (7.2)]. 2.6 Dose Modifications for Patients with Renal Impairment Patients with mild renal impairment (CLcr 51-80 mL/min as estimated by Cockcroft-Gault) do not require an adjustment in Lynparza dosing. In patients with moderate renal impairment (CLcr 31-50 mL/min) the recommended dose reduction is to 300 mg (six 50 mg capsules) taken twice daily, for a total daily dose of 600 mg. The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. 3 DOSAGE FORMS AND STRENGTHS Capsules (50 mg): white, opaque, marked in black ink with “OLAPARIB 50 mg” on the cap and the AstraZeneca logo on the body. 4 CONTRAINDICATIONS None. 5 WARNINGS AND PRECAUTIONS 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) have been confirmed in 6 out of 298 (2%) patients enrolled in a single arm trial of Lynparza monotherapy, in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced cancers. In a randomized placebo controlled trial, MDS/AML occurred in 3 out of 136 (2%) patients with advanced ovarian cancer treated with Lynparza. Overall, MDS/AML were reported in <1% patients treated with Lynparza in clinical studies. The majority of MDS/AML reports were fatal, and the duration of therapy with Lynparza in patients who developed secondary MDS/cancer-therapy related AML varied from <6 months to >2 years. All of these patients had previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. Some of these patients also had a history of previous cancer or of bone marrow dysplasia. Monitor complete blood count testing at baseline and monthly thereafter. Do not start Lynparza until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1). For prolonged hematological toxicities, interrupt Lynparza and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Lynparza. 3 Reference ID: 4140741 5.2 Pneumonitis Pneumonitis, including fatal cases, occurred in <1% of patients treated with Lynparza. If patients present with new or worsening respiratory symptoms such as dyspnea, fever, cough, wheezing, or a radiological abnormality occurs, interrupt treatment with Lynparza and initiate prompt investigation. If pneumonitis is confirmed, discontinue Lynparza. 5.3 Embryo-Fetal Toxicity Lynparza can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. In an animal reproduction study, administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily. Apprise pregnant women of the potential hazard to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Lynparza [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)]. 6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling:  Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1)]  Pneumonitis [see Warnings and Precautions (5.2)] 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Lynparza 400 mg twice daily as monotherapy, has been studied in 300 patients with gBRCA-mutated advanced ovarian cancer, and 223 of these patients had received 3 or more prior lines of chemotherapy. In the 223 patients with gBRCA-mutated ovarian cancer who received 3 or more prior lines of chemotherapy (including 137 patients in Study 1 with measureable disease) [see Clinical Studies (14)] adverse reactions led to dose interruption in 40% of patients, dose reduction in 4%, and discontinuation in 7%. There were 8 (4%) patients with adverse reactions leading to death, two were attributed to acute leukemia, and one each was attributed to COPD, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, and suture rupture. The median exposure to Lynparza in these patients was 158 days. Table 1 and Table 2 summarize the common adverse reactions and abnormal laboratory findings, respectively, observed in patients treated with Lynparza. 4 Reference ID: 4140741 Table 1 Adverse Reactions Reported in ≥20% of Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza Adverse Reaction 3 or more lines of prior chemotherapy Grades 1-4 N=223 % Grades 3-4 N=223 % Blood and Lymphatic disorders Anemia 34 18 Gastrointestinal disorders Abdominal pain/discomfort 43 8 Decreased appetite 22 1 Nausea 64 3 Vomiting 43 4 Diarrhea 31 1 Dyspepsia 25 0 General disorders Fatigue/asthenia 66 8 Infections and infestations Nasopharyngitis/URI 26 0 Musculoskeletal and Connective Tissue disorders Arthralgia/musculoskeletal pain 21 0 Myalgia 22 0 Table 2 Laboratory Abnormalities Reported in ≥25% Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza Laboratory Parameter* 3 or more lines of prior chemotherapy Grades 1-4 N=223 % Grades 3-4 N=223 % Decrease in hemoglobin 90 15 Decrease in absolute neutrophil count 25 7 Decrease in platelets 30 3 Decrease in lymphocytes 56 17 Mean corpuscular volume elevation 57 -Increase in creatinine* 30 2 * Patients were allowed to enter clinical studies with laboratory values of Grade 1. The following adverse reactions and laboratory abnormalities have been identified in ≥10 to <20% of the 223 patients receiving Lynparza and not included in the table: cough, constipation, dysgeusia, peripheral edema, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash. The following adverse reactions and laboratory abnormalities have been identified in ≥1 to <10% of the 223 patients receiving Lynparza and not included in the table: leukopenia, stomatitis, peripheral neuropathy, pyrexia, hypomagnesemia, hyperglycemia, anxiety, depression, insomnia, dysuria, urinary incontinence, vulvovaginal disorder, dry skin/ eczema, pruritus, hypertension, venous thrombosis (including pulmonary embolism), and hot flush. 5 Reference ID: 4140741 Table 3 presents adverse reactions reported in ≥20% of patients from a randomized trial of Lynparza 400 mg twice daily as maintenance monotherapy compared to placebo in patients with platinum sensitive, relapsed, high-grade serous ovarian cancer following treatment with 2 or more platinum-containing regimens. Table 4 presents the laboratory abnormalities in patients from this randomized trial. Of the 96 patients with gBRCA-mutation, 53 received Lynparza, and 43 received placebo. The median duration on treatment with Lynparza was 11.1 months for patients with a gBRCA-mutation compared to 4.4 months for patients with gBRCA-mutation on placebo. Adverse reactions led to dose interruptions in 26% of those receiving Lynparza and 7% of those receiving placebo; dose reductions in 15% of Lynparza and 5% of placebo patients; and discontinuation in 9% of Lynparza and 0% in placebo patients. One (2%) patient on Lynparza died as a result of an adverse reaction. Table 3 Adverse Reactions Reported in ≥20% of Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial Adverse Reactions Lynparza N=53 Placebo N=43 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Blood and Lymphatic disorders Anemia 25 4 7 2 Gastrointestinal disorders Abdominal pain/discomfort 47 0 58 2 Decreased appetite 25 0 14 0 Nausea 75 2 37 0 Vomiting 32 4 9 0 Diarrhea 28 4 21 2 Dyspepsia 25 0 14 0 Dysgeusia 21 0 9 0 General disorders Fatigue (including asthenia, lethargy) 68 6 53 2 Infections and infestations Nasopharyngitis/Pharyngitis/URI 43 0 16 0 Musculoskeletal and Connective tissue disorders Arthralgia/Musculoskeletal pain 32 4 21 0 Myalgia 25 2 12 0 Back pain 25 6 21 0 Nervous system disorder Headache 25 0 19 2 Respiratory, Thoracic, Mediastinal disorders Cough 21 0 14 0 Skin and Subcutaneous Tissue Dermatitis/Rash 25 0 14 0 6 Reference ID: 4140741 Table 4 Laboratory Abnormalities in ≥25% Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial Laboratory parameter* Lynparza N=53 Placebo N=43 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Decrease in hemoglobin 85 8 58 2 Decrease in absolute neutrophil count 32 8 23 0 Decrease in platelets 26 6 19 0 Mean corpuscular volume elevation 85 -44 -Increase in creatinine* 26 0 5 0 * Patients were allowed to enter clinical studies with laboratory values of Grade 1. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Lynparza. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: Hypersensitivity (rash/dermatitis) 7 DRUG INTERACTIONS 7.1 Anticancer Agents Clinical studies of Lynparza in combination with other myelosuppressive anticancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. 7.2 Drugs That May Increase Olaparib Plasma Concentrations Olaparib is primarily metabolized by CYP3A. In patients (N=57), co-administration of itraconazole, a strong CYP3A inhibitor, increased AUC of olaparib by 2.7-fold. A moderate CYP3A inhibitor, fluconazole, is predicted to increase the AUC of olaparib by 2.2-fold. Avoid concomitant use of strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) and moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil). If the strong or moderate CYP3A inhibitors must be co-administered, reduce the dose of Lynparza [see Dosage and Administration (2.4)]. Avoid grapefruit and Seville oranges during Lynparza treatment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. 7 Reference ID: 4140741 7.3 Drugs That May Decrease Olaparib Plasma Concentrations In patients (N=22), co-administration of rifampicin, a strong CYP3A inducer, decreased AUC of olaparib by 87%. A moderate CYP3A inducer, efavirenz, is predicted to decrease the AUC of olaparib by approximately 50%. Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampicin, carbamazepine, St. John’s Wort) and moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin). If a moderate CYP3A inducer cannot be avoided, be aware of a potential for decreased efficacy of Lynparza [see Clinical Pharmacology (12.3)]. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily [see Data]. Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies. Data Animal Data In a fertility and early embryonic development study in female rats, olaparib was administered orally for 14 days before mating through to day 6 of pregnancy, which resulted in increased post-implantation loss at a dose level of 15 mg/kg/day (with maternal systemic exposures approximately 11% of the human exposure (AUC0-24h) at the recommended dose). In an embryo-fetal development study, pregnant rats received oral doses of 0.05 and 0.5 mg/kg/day olaparib during the period of organogenesis. A dose of 0.5 mg/kg/day (with maternal systemic exposures approximately 0.3% of human exposure (AUC0-24h) at the recommended dose) caused embryo-fetal toxicities including increased post-implantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital) and diaphragm (hernia). Additional abnormalities or variants included incomplete or absent ossification (vertebrae/sternebrae, ribs, limbs) and other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter and umbilical artery. Some findings noted above in the eyes, ribs and ureter were observed at a dose of 0.05 mg/kg/day olaparib at lower incidence. 8 Reference ID: 4140741 8.2 Lactation Risk Summary No data are available regarding the presence of olaparib in human milk, or on its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infants from Lynparza, advise a lactating woman not to breastfeed during treatment with Lynparza and for one month after receiving the last dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with Lynparza. Contraception Females Lynparza can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use highly effective contraception during treatment with Lynparza and for at least 6 months following the last dose. 8.4 Pediatric Use The safety and efficacy of Lynparza have not been established in pediatric patients. 8.5 Geriatric Use In clinical studies of Lynparza enrolling 735 patients with advanced solid tumors [the majority (69%) of whom had ovarian cancer] who received Lynparza 400 mg twice daily as monotherapy, 148 (20%) of patients were aged ≥65 years. The safety profile was similar irrespective of age with the exception of AEs of CTCAE ≥3 which were reported more frequently in patients aged ≥65 years (53.4%) than those <65 years (43.4%). No individual adverse event or System Organ Class accounted for this observed difference. 8.6 Hepatic Impairment No adjustment to the starting dose is required in patients with mild hepatic impairment. A 1.2-fold increase in mean exposure (AUC) was observed in patients with mild hepatic impairment (based on Child-Pugh classification A) compared to patients with normal hepatic function. There are no data in patients with moderate or severe hepatic impairment [see Clinical Pharmacology (12.3)]. 8.7 Renal Impairment A 1.2-fold increase in mean exposure (AUC) was observed in patients with mild renal impairment (CLcr = 51-80 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). No dose adjustment to the starting dose is required in patients with mild renal impairment, but patients should be monitored closely for toxicity. A 1.4-fold increase in AUC was observed in patients with moderate renal 9 Reference ID: 4140741 impairment (CLcr = 31-50 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). For patients with moderate renal impairment, reduce the dose of Lynparza to 300 mg twice daily [see Dosage and Administration (2.5)]. There are no data in patients with severe renal impairment or end-stage disease (CLcr ≤30 mL/min) [see Clinical Pharmacology (12.3)]. 10 OVERDOSAGE There is no specific treatment in the event of Lynparza overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should follow general supportive measures and should treat symptomatically. 11 DESCRIPTION Olaparib is an inhibitor of the mammalian polyadenosine 5’-diphosphoribose polymerase (PARP) enzyme. The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4­ fluorophenyl)methyl]phthalazin-1(2H)-one and it has the following chemical structure: The empirical molecular formula for Lynparza is C24H23FN4O3 and the relative molecular mass is 434.46. Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility of approximately 0.1 mg/mL across the physiological pH range. Lynparza is available in 50 mg capsules for oral administration. Each capsule contains olaparib as the active ingredient and the following inactive ingredients:  Capsule content: lauroyl polyoxylglycerides  Capsule shell: hypromellose, titanium dioxide, gellan gum, potassium acetate  Capsule printing ink: shellac, ferrosoferric oxide 10 Reference ID: 4140741 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death. 12.3 Pharmacokinetics Absorption Following oral administration of olaparib via the capsule formulation, absorption is rapid with peak plasma concentrations typically achieved between 1 to 3 hours after dosing. On multiple dosing there is no marked accumulation (accumulation ratio of 1.4 – 1.5 for twice daily dosing), with steady state exposures achieved within 3 to 4 days. Limited data suggest that the systemic exposure (AUC) of olaparib increases less than proportionally with dose over the dose range of 100 to 400 mg, but the PK data were variable across trials. Co-administration with a high fat meal slowed the rate (Tmax delayed by 2 hours) of absorption, but did not significantly alter the extent of olaparib absorption (mean AUC increased by approximately 20%). Distribution Olaparib had a mean ( standard deviation) apparent volume of distribution at steady state of 167  196 L after a single 400 mg dose of olaparib. The in vitro protein binding of olaparib at plasma concentrations achieved following dosing at 400 mg twice daily is approximately 82%. Metabolism In vitro, CYP3A4 was shown to be the enzyme primarily responsible for the metabolism of olaparib. Following oral dosing of 14C-olaparib to female patients, unchanged olaparib accounted for the majority of the circulating radioactivity in plasma (70%). It was extensively metabolized with unchanged drug accounting for 15% and 6% of radioactivity in urine and feces, respectively. The majority of the metabolism is attributable to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation. Excretion A mean ( standard deviation) terminal plasma half-life of 11.9  4.8 hours and apparent plasma clearance of 8.6  7.1 L/h were observed after a single 400 mg dose of olaparib. 11 Reference ID: 4140741 Following a single dose of 14C-olaparib, 86% of the dosed radioactivity was recovered within a 7-day collection period, 44% via the urine and 42% via the feces. The majority of the material was excreted as metabolites. Drug Interactions Based on the data from a drug-interaction trial (N=57), the AUC and Cmax of olaparib increased by 2.7- and 1.4-fold, respectively, when olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) may increase the AUC and Cmax of olaparib by 2.2- and 1.2-fold, respectively. Based on the data from a drug-interaction trial (N=22), the AUC and Cmax of olaparib decreased by 87% and 71%, respectively, when olaparib was administered in combination with rifampicin, a strong CYP3A inducer. Simulations suggested that a moderate CYP3A inducer (efavirenz) may decrease the AUC and Cmax of olaparib by approximately 50% and 30%, respectively. In vitro studies have shown that olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Simulations suggested that olaparib may not affect the exposure of a CYP3A substrate in humans. It cannot be excluded that olaparib may induce CYP2C9 and CYP2C19. In vitro studies also indicated that olaparib is a substrate of P-gp and an inhibitor of P-gp (MDR1), BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. The clinical relevance of these findings is unknown. The potential for olaparib to induce P-gp has not been evaluated. Pharmacokinetics in Specific Populations Hepatic Impairment In a hepatic impairment trial, the mean AUC increased by 15% and the mean Cmax by 13% when olaparib was dosed in patients with mild hepatic impairment (Child-Pugh classification A; N=9) compared with patients with normal hepatic function (N=13). Mild hepatic impairment had no effect on the protein binding of olaparib and therefore total plasma exposure was representative of free drug. There are no data in patients with moderate or severe hepatic impairment. Renal Impairment In a dedicated renal impairment trial, the mean AUC and Cmax of olaparib both increased by 1.2-fold, when olaparib was dosed in patients with mild renal impairment (CLcr = 51-80 mL/min defined by the Cockcroft-Gault equation; N=13) and by 1.4- and 1.3-fold, respectively, when olaparib was dosed in patients with moderate renal impairment (CLcr = 31-50 mL/min; N=13), compared to those with normal renal function (CLcr ≥81 mL/min; N=12). There was no evidence of a relationship between the extent of plasma protein binding of olaparib and creatinine clearance. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤ 30 mL/min). 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with olaparib. 12 Reference ID: 4140741 Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian CHO cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of olaparib and indicates potential for genotoxicity in humans. Olaparib was not mutagenic in a bacterial reverse mutation (Ames) test. In a fertility study, female rats received oral olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before mating through the first week of pregnancy. There were no adverse effects on mating and fertility rates at doses up to 15 mg/kg/day (maternal systemic exposures approximately 11% of the human exposure (AUC0-24h) at the recommended dose). In a male fertility study, olaparib had no effect on mating and fertility in rats at oral doses up to 40 mg/kg/day following at least 70 days of olaparib treatment (with systemic exposures of approximately 7% of the human exposure (AUC0-24h) at the recommended dose). 14 CLINICAL STUDIES The efficacy of Lynparza was investigated in a single-arm study in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced cancers (Study 1). A total of 137 patients with measurable, gBRCAm-associated ovarian cancer treated with three or more prior lines of chemotherapy were enrolled. All patients received Lynparza at a dose of 400 mg twice daily as monotherapy until disease progression or intolerable toxicity. Objective response rate (ORR) and duration of response (DOR) were assessed by the investigator according to RECIST v1.1. The median age of the patients was 58 years, the majority were Caucasian (94%) and 93% had an ECOG PS of 0 or 1. Deleterious or suspected deleterious, germline BRCA-mutation status was verified retrospectively in 97% (59/61) of the patients for whom blood samples were available by the companion diagnostic BRACAnalysis CDxTM, which is FDA approved for selection of patients for Lynparza treatment. Efficacy results from Study 1 are summarized in Table 5. Table 5 Overall Response and Duration of Response in Patients with gBRCA-mutated Advanced Ovarian Cancer Who Received 3 or More Prior Lines of Chemotherapy in Study 1 N=137 Objective Response Rate (95% CI) 34% (26, 42) Complete Response 2% Partial Response 32% Median DOR in months (95% CI) 7.9 (5.6, 9.6) 13 Reference ID: 4140741 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Lynparza 50 mg is a white, opaque, hard capsule, marked in black ink with: “OLAPARIB 50 mg” on the cap and AstraZeneca logo on the body; available in: Bottles of 112 capsules NDC 0310-0657-58 16.2 Storage Store at 25ºC (77F), excursions permitted to 15ºC -30ºC (59F -86F) [see USP Controlled Room Temperature] Lynparza should not be exposed to temperatures greater than 40ºC or 104ºF. Do not take Lynparza if it is suspected of having been exposed to temperatures greater than 40ºC or 104ºF. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).  Dosing Instructions: Inform patients on how to take Lynparza [see Dosage and Administration (2.2)]. Lynparza should be taken twice daily with or without food. Instruct patients that if they miss a dose of Lynparza, not to take an extra dose to make up for the one that they missed. They should take their next normal dose at the usual time. Each capsule should be swallowed whole. Do not chew, dissolve, or open the capsule. Patient should not take Lynparza with grapefruit or Seville oranges.  Inform patients not to substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation [see Dosage and Administration (2.2)].  MDS/AML: Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. This may be a sign of hematological toxicity or a more serious uncommon bone marrow problem called ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukemia’ (AML) which have been reported in patients treated with Lynparza [see Warnings and Precautions (5.1)].  Pneumonitis: Advise patients to contact their healthcare provider if they experience any new or worsening respiratory symptoms including shortness of breath, fever, cough, or wheezing [see Warnings and Precautions (5.2)].  Embryo-Fetal Toxicity: Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for 6 months after receiving the last dose [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1, 8.3)].  Lactation: Advise patients not to breastfeed while taking Lynparza and for one month after receiving the last dose [see Use in Special Populations (8.2)]. 14 Reference ID: 4140741  Nausea/vomiting: Advise patients that mild or moderate nausea and/or vomiting is very common in patients receiving Lynparza and that they should contact their healthcare provider who will advise on available antiemetic treatment options. 15 Reference ID: 4140741 Medication Guide Lynparza (Lin-par-zah) (olaparib) capsules What is the most important information I should know about Lynparza? Lynparza may cause serious side effects that can lead to death, including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Lynparza. If you develop MDS or AML, your healthcare provider will stop treatment with Lynparza. Symptoms of low blood cell counts are common during treatment with Lynparza, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include: o weakness o weight loss o fever o frequent infections o blood in urine or stool o shortness of breath o feeling very tired o bruising or bleeding more easily Your healthcare provider will do blood tests to check your blood cell counts: o before treatment with Lynparza o every month during treatment with Lynparza o weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Lynparza until your blood cell counts improve. Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily stop treatment or completely stop treatment if you develop pneumonitis. Tell your healthcare provider if you have any of the symptoms above during treatment with Lynparza. What is Lynparza? Lynparza is a prescription medicine used to treat women with advanced ovarian cancer who:  have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and  have a certain type of abnormal inherited BRCA gene. Your healthcare provider will perform a test to make sure that Lynparza is right for you. It is not known if Lynparza is safe and effective in children. 16 Reference ID: 4140741 What should I tell my healthcare provider before taking Lynparza? Before you take Lynparza, tell your healthcare provider about all of your medical conditions including if you:  have lung or breathing problems  have liver problems  have kidney problems  are pregnant or plan to become pregnant. Lynparza can harm your unborn baby and may cause loss of pregnancy (miscarriage). o If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Lynparza. o Females who are able to become pregnant should use effective birth control (contraception) during treatment with Lynparza and for 6 months after receiving the last dose of Lynparza. o Talk to your healthcare provider about birth control methods that may be right for you. o Tell your healthcare provider right away if you become pregnant.  are breastfeeding or plan to breastfeed. It is not known if Lynparza passes into your breast milk. Do not breastfeed during treatment with Lynparza and for 1 month after receiving the last dose of Lynparza. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the­ counter medicines, vitamins, and herbal supplements. Taking Lynparza and certain other medicines may affect how Lynparza works and may cause side effects. How should I take Lynparza?  Take Lynparza exactly as your healthcare provider tells you.  Your healthcare provider may temporarily stop treatment with Lynparza or change your dose of Lynparza if you have side effects.  Lynparza comes as capsules and tablets. Lynparza capsules and tablets are not the same. If your healthcare provider prescribes Lynparza capsules for you do not take Lynparza tablets. If you have any questions about Lynparza, talk with your healthcare provider or pharmacist.  Take Lynparza by mouth 2 times a day. Each dose should be taken 12 hours apart.  Take Lynparza with or without food.  Swallow Lynparza capsules whole. Do not chew, dissolve, or open the capsules.  Do not take Lynparza capsules if they look damaged or show signs of leakage.  If you miss a dose of Lynparza, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose.  If you take too much Lynparza, call your healthcare provider or go to the nearest hospital emergency room right away. What should I avoid while taking Lynparza?  Avoid grapefruit, grapefruit juice and Seville oranges during treatment with Lynparza. Grapefruit and Seville oranges may increase the level of Lynparza in your blood. 17 Reference ID: 4140741 What are the possible side effects of Lynparza? Lynparza may cause serious side effects. See “What is the most important information I should know about Lynparza?” The most common side effects of Lynparza are:  nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.  tiredness or weakness  diarrhea  indigestion or heartburn  headache  loss of appetite  changes in the way food tastes  changes in kidney function blood test  sore throat or runny nose  upper respiratory infection  cough  pain in the joints, muscles, and back  rash  pain or discomfort in the stomach area These are not all the possible side effects of Lynparza. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA­ 1088. How should I store Lynparza?  Store Lynparza at room temperature, between 68°F to 77°F (20°C to 25°C).  Do not store Lynparza at temperatures greater than 104°F (40°C). Do not take Lynparza if you think it may have been stored at a temperature greater than 104°F (40°C). Keep Lynparza and all medicines out of the reach of children. General information about the safe and effective use of Lynparza Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Lynparza for a condition for which it was not prescribed. Do not give Lynparza to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Lynparza that is written for health professionals. What are the ingredients in Lynparza? Active ingredient: olaparib Inactive ingredients: Capsule contains: lauroyl polyoxylglycerides Capsule shell contains: hypromellose, titanium dioxide, gellan gum, potassium acetate Capsule printing ink contains: shellac, ferrosoferric oxide Lynparza is a trademark of the AstraZeneca group of companies. ©AstraZeneca 2017 Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 For more information, call 1-800-236-9933 or go to www.Lynparza.com. This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 8/2017 18 Reference ID: 4140741 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206162Orig1s007 OFFICER/EMPLOYEE LIST Officer/Employee List Application: NDA 206162/S-007 Lynparza® (Olaparib), Oral Capsules The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list: Balasubramaniam, Sanjeeve Beaver, Julia A. Griffiths, LaShawn Ison, Gwynn Mills, Sharon Pierce, William Venugopal, Rajesh Wright, Kevin Reference ID: 4144789 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206162Orig1s007 MEDICAL REVIEW(S) 1 Division of Oncology Products 1 CLINICAL TEAM LEADER LABELING REVIEW Application: NDA 206162/S-007 Name of Drug: LYNPARZATM (olaparib) Capsules, 50 mg Applicant: AstraZeneca, LP Labeling Reviewed Submission Date: May 17, 2017 Receipt Date: May 17, 2017 Background and Summary Description: NDA 206162, olaparib capsules, is currently under accelerated approval. Supplement 007 was submitted by AstraZeneca on May 17, 2017 to add Section 6.2 to the USPI to add the post-marketing signal of “hypersensitivity characterized by rash and dermatitis” based on new data. After review of the justification for this addition, it was determined by the review team that it is reasonable to add this proposed language to Section 6.2 of the olaparib USPI.\nNDA 208558, the tablet formulation of olaparib, which has a different bioavailability profile and is therefore non-interchangeable with the capsule formulation under accelerated approval, is due for a regular approval action by the PDUFA goal date of August 22, 2017. Because both the tablet and the capsule formulations will be on the market under the same proprietary name simultaneously, the applicant and Agency, including DMEPA, discussed specific strategies to minimize the potential for medication errors.\nOne action FDA has decided to take to aid in this risk mitigation is to update olaparib capsule labeling for NDA 206162 to add text regarding the lack of interchangeability of the two products in the Highlights, Section 2, and Medication Guide.\nThe Highlights section will read, “To avoid substitution errors and overdose, do not substitute Lynparza capsules with Lynparza tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.” Section 2.2 will read, “Lynparza is also available as 100 mg and 150 mg tablets. DO NOT substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation Refer to the full prescribing information for Lynparza tablets for specific tablet dosing.” The Medication Guide will read, “Lynparza comes as capsules and tablets. Lynparza capsules and tablets are not the same. If your healthcare provider prescribes Lynparza capsules for you do not take Lynparza tablets. If you have any questions about Lynparza, talk with your healthcare provider or pharmacist.” Reference ID: 4138504 (b) (4) 2 The approval of NDA 208558 for the tablet formulation of olaparib will also change the accelerated approval of NDA 206162 for the fourth-and-beyond line of treatment of women with germline BRCA mutation-associated ovarian cancer to regular approval.\nIn order to fulfill the accelerated approval PMRs for NDA 206162, reference must be made to the clinical trial submitted to NDA 208558. This cross-reference will allow the warnings regarding non-interchangeability to be added to NDA 206162/S-007, and allow the removal of the accelerated approval language from the Highlights and Section 1 of the USPI for olaparib capsules.\nThe Agency has asked AstraZeneca to submit to NDA 206162/S-007 a letter of cross reference to the tablet NDA (208558). This will allow the cross-referencing of the Clinical Study Report for SOLO2, submitted to NDA 208558, to fulfill PMR 2824-1 of NDA 206162. Supplement 007, originally submitted as a labeling supplement, will be converted to an SE-7 efficacy supplement, as clinical data are needed to support the non-interchangeability language between capsule and tablet formulations and the change to regular approval for the fourth-line indication. In addition, the second Subpart H PMR from NDA 206162 (PMR 2824-2) will be released and reissued as a PMC for NDA 208558.\nRecommendation Approval of NDA 206162/S-007 is recommended. A letter of cross-reference should be issued by AstraZeneca to fulfill PMR 2824-1. PMR 2824-2 will be released from NDA 206162 and reissued as a PMC in the approval letter for NDA 208558. Labeling should be modified as described above.\nGwynn Ison, MD Medical Officer, DOP1 Sanjeeve Balasubramaniam, MD, MPH Clinical Team Leader (Acting), DOP1 Reference ID: 4138504 ---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.\n---------------------------------------------------------------------------------------------------------/s/ ----------------------------------------------------GWYNN ISON 08/11/2017 SANJEEVE BALASUBRAMANIAM 08/11/2017 Reference ID: 4138504 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206162Orig1s007 OTHER REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Medical Policy PATIENT LABELING REVIEW Date: August 1, 2017 To: Julia Beaver, MD Acting Director Division of Oncology Products 1 (DOP1) Through: LaShawn Griffiths, MSHS-PH, BSN, RN Associate Director for Patient Labeling Division of Medical Policy Programs (DMPP) Shawna Hutchins, MPH, BSN, RN Senior Patient Labeling Reviewer Division of Medical Policy Programs (DMPP) From: Sharon R. Mills, BSN, RN, CCRP Senior Patient Labeling Reviewer Division of Medical Policy Programs (DMPP) Kevin Wright, PharmD Regulatory Review Officer Office of Prescription Drug Promotion (OPDP) Subject: Review of Patient Labeling: Medication Guide (MG) Drug Name (established name): LYNPARZA (olaparib) Dosage Form and Route: capsules, for oral use Application Type/Number: NDA 206162 Supplement Number: S-007 and S-008 Applicant: AstraZeneca Pharmaceuticals, LP Reference ID: 4133219 1 INTRODUCTION On May 17, 2017, AstraZeneca Pharmaceuticals LP submitted for the Agency’s review a Prior Approval Supplement (PAS) - Labeling to their approved New Drug Application (NDA) 206162/S-007 for LYNPARZA (olaparib) capsules. The purpose of this supplement is to update the approved product labeling with updated information on the post-marketing signal of hypersensitivity characterized by rash and dermatitis based on new data. On June 8, 2017, AstraZeneca Pharmaceuticals LP submitted for the Agency’s review a PAS- Labeling to their approved NDA 206162/S-008 for LYNPARZA (olaparib) capsules. The purpose of this supplement is to update the approved product labeling with updated information on the relative bioavailability of the capsule and tablet formulations of olaparib. LYNPARZA (olaparib) tablets was originally approved on December 9, 2014, and is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. This collaborative review is written by the Division of Medical Policy Programs (DMPP) and the Office of Prescription Drug Promotion (OPDP) in response to a request by the Division of Oncology Products 1 (DOP1) on July 25, 2017, for DMPP and OPDP to review the Applicant’s proposed Medication Guide (MG) for LYNPARZ (olaparib) capsules. 2 MATERIAL REVIEWED • Draft LYNPARZA (olaparib) capsules MG received on June 27, 2017, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on July 25, 2017. • Draft LYNPARZA (olaparib) capsules Prescribing Information (PI) received on June 27, 2017, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on July 25, 2017. • Approved LYNPARZA (olaparib) capsules labeling dated January 26, 2017. 3 REVIEW METHODS In our collaborative review of the MG we: • simplified wording and clarified concepts where possible • ensured that the MG is consistent with the Prescribing Information (PI) • removed unnecessary or redundant information • ensured that the MG is free of promotional language or suggested revisions to ensure that it is free of promotional language • ensured that the MG meets the Regulations as specified in 21 CFR 208.20 Reference ID: 4133219 • ensured that the MG meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006) 4 CONCLUSIONS The MG is acceptable with our recommended changes. 5 RECOMMENDATIONS • Please send these comments to the Applicant and copy DMPP and OPDP on the correspondence. • Our collaborative review of the MG is appended to this memorandum. Consult DMPP and OPDP regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the MG. Please let us know if you have any questions. Reference ID: 4133219 6 Page(s) of Draft Labeling has been Withheld in Full as b4 (CCI/TS) immediately following this page ---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.\n---------------------------------------------------------------------------------------------------------/s/ ----------------------------------------------------SHARON R MILLS 08/01/2017 KEVIN WRIGHT 08/02/2017 LASHAWN M GRIFFITHS 08/02/2017 Reference ID: 4133219 1 ****Pre-decisional Agency Information**** Memorandum Date: July 31, 2017 To: Rajesh Venugopal, MPH, MBA Senior Regulatory Project Manager Division of Oncology Products 1 Office of Hematology and Oncology Products From: Kevin Wright, PharmD Regulatory Review Officer Office of Prescription Drug Promotion (OPDP) Subject: Lynparza® (olaparib) capsules, for oral use NDA 206162 Supplement 007 and 008 Office of Prescription Drug Promotion comments on proposed prescribing information (PI) Office of Prescription Drug Promotion (OPDP) has reviewed the draft prescribing information (PI) for Lynparza® (olaparib) capsules, for oral use as requested by DOP1 in the consult dated July 25, 2017. Supplement 007 is a prior approval supplement that proposes inclusion of hypersensitivity reactions into the Postmarketing Experience section of the PI.\nSupplement 008 is a prior approval supplement that proposes inclusion of bioavailability data between the tablet and capsule formulation of Lynparza.\nOPDP’s review of the proposed PI is based on the draft PI titled, “SLR_007_008_NDA 206162_Combined annotated-draft-label_Submitted 6.22.17.doc” sent by electronic mail on July 25, 2017, to OPDP (Kevin Wright) from DOP1 (Rajesh Venugopal). OPDP has no comments on the proposed PI.\nThe combined OPDP and Division of Medical Policy Programs (DMPP) review of the patient package insert (PPI) will be provided under a separate cover.\nIf you have any questions, please feel free to contact, Kevin Wright at (301) 796-3621 or kevin.wright@fda.hhs.gov. OPDP appreciates the opportunity to provide comments on these materials. Thank you!\nFOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion Reference ID: 4132770 ---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.\n---------------------------------------------------------------------------------------------------------/s/ ----------------------------------------------------KEVIN WRIGHT 07/31/2017 Reference ID: 4132770"
      }
    ]
  },
  "firm_searches": {}
}